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Abstract
Anti-NMDA receptor and anti-AMPA receptor (NMDAR and AMPAR) encephalitides are debilitating but
reversible autoimmune diseases of glutamatergic synapses of the central nervous system. Consistent
with disruption of the major excitatory neurotransmitter in the central nervous system, symptoms of these
newly characterized diseases are severe and include psychosis, memory loss, confusion, seizures, and
autonomic instability. Previous work has shown that patients produce antibodies that can be detected in
serum and cerebrospinal fluid that bind to NMDARs or AMPARs, causing their internalization and
depletion from neuronal membranes and synapses. The goal of my thesis was to determine the
mechanisms of patient antibody-mediated pathology and the compensatory responses of neurons upon
antibody exposure. I used dissociated hippocampal neurons and organotypic hippocampal slice cultures
for molecular (immunostaining, Western blotting, and quantitative PCR) and electrophysiological (wholecell and extracellular recordings) studies.
I found that antibodies from patients with anti-NMDAR or anti-AMPAR encephalitis caused internalization
of their respective receptors. This internalization was stimulated by receptor cross-linking by patient
immunoglobulins. Antibody-bound, internalized receptors trafficked through both recycling and lysosomal
intracellular compartments. The loss of receptors was specific, time-dependent, reversible upon antibody
removal, and did not result in neuronal death or structural dismantling of excitatory synapses. No acute
effects on receptor function were detected. In response to the decreased glutamate signaling, neurons
engage homeostatic plasticity mechanisms to maintain action potential firing rate, including downregulating inhibitory synapses and increasing intrinsic excitability. Additionally, treatment with antiAMPAR antibodies altered patterns of spontaneous action potential firing. Finally, a hippocampal slice
culture model of anti-NMDAR antibody exposure was developed and validated for use in future studies.
My work demonstrates that the hypoglutamatergic state created by anti-glutamate receptor antibodies
leads to both direct and compensatory cellular and synaptic changes. Homeostatic plasticity of inhibition
and intrinsic excitability opposes the declining excitatory synaptic transmission, but without the
preservation of action potential firing pattern. Together, the direct and compensatory plasticity caused by
patient antibodies may change the activity and thus the function of key brain circuits, contributing to
patients' cognitive and behavioral symptoms.
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CELLULAR AND SYNAPTIC HOMEOSTATIC PLASTICITY IN
RESPONSE TO LOSS OF GLUTAMATERGIC
TRANSMISSION: INSIGHTS FROM ANTI-GLUTAMATE
RECEPTOR ENCEPHALITIDES
Emilia Harrington Moscato
Rita J. Balice-Gordon, Ph.D.

Anti-NMDA receptor and anti-AMPA receptor (NMDAR and AMPAR) encephalitides are
debilitating but reversible autoimmune diseases of glutamatergic synapses of the central nervous
system. Consistent with disruption of the major excitatory neurotransmitter in the central nervous
system, symptoms of these newly characterized diseases are severe and include psychosis,
memory loss, confusion, seizures, and autonomic instability. Previous work has shown that
patients produce antibodies that can be detected in serum and cerebrospinal fluid that bind to
NMDARs or AMPARs, causing their internalization and depletion from neuronal membranes and
synapses. The goal of my thesis was to determine the mechanisms of patient antibody-mediated
pathology and the compensatory responses of neurons upon antibody exposure. I used
dissociated hippocampal neurons and organotypic hippocampal slice cultures for molecular
(immunostaining, Western blotting, and quantitative PCR) and electrophysiological (whole-cell
and extracellular recordings) studies.
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I found that antibodies from patients with anti-NMDAR or anti-AMPAR encephalitis
caused internalization of their respective receptors. This internalization was stimulated by
receptor cross-linking by patient immunoglobulins. Antibody-bound, internalized receptors
trafficked through both recycling and lysosomal intracellular compartments. The loss of receptors
was specific, time-dependent, reversible upon antibody removal, and did not result in neuronal
death or structural dismantling of excitatory synapses. No acute effects on receptor function were
detected. In response to the decreased glutamate signaling, neurons engage homeostatic
plasticity mechanisms to maintain action potential firing rate, including down-regulating inhibitory
synapses and increasing intrinsic excitability. Additionally, treatment with anti-AMPAR antibodies
altered patterns of spontaneous action potential firing. Finally, a hippocampal slice culture model
of anti-NMDAR antibody exposure was developed and validated for use in future studies.
My work demonstrates that the hypoglutamatergic state created by anti-glutamate
receptor antibodies leads to both direct and compensatory cellular and synaptic changes.
Homeostatic plasticity of inhibition and intrinsic excitability opposes the declining excitatory
synaptic transmission, but without the preservation of action potential firing pattern. Together, the
direct and compensatory plasticity caused by patient antibodies may change the activity and thus
the function of key brain circuits, contributing to patients’ cognitive and behavioral symptoms.
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PREFACE

Recent years have led to remarkable progress in the diagnosis and treatment of
autoimmune diseases of the central nervous system, including poorly understood inflammatory
encephalitides such as limbic encephalitis. Beginning in 2007, with the discovery of anti-NMDA
receptor (NMDAR) antibodies in the cerebrospinal fluid and serum of a group of women with
1

ovarian teratomas and neuropsychiatric deterioration, the repertoire of autoimmune
encephalitides in which synaptic antigens are targeted has expanded to encompass anti-AMPA
receptor (AMPAR), anti-GABAA and GABAB receptor, anti-glycine receptor, anti-metabotropic
glutamate receptors type 1 and 5 (mGluR1 and mGluR5), anti-voltage-gated potassium channel,
2

anti-LGI, and anti-CASPR2 encephalitis. Recognition of non-paraneoplastic cases, i.e. patients
with no detectable tumors, and the prevalence of the disease across gender and age, has further
enhanced our understanding of disease etiology and has contributed to more rapid diagnosis.
While symptoms and prevalence vary among subtypes of these disorders, a common feature is
central nervous system dysfunction caused by disruption of synaptic and neuronal function by
autoantibodies associated with each disorder.
My thesis is an investigation of the mechanisms of two antibody-mediated encephalitides,
anti-NMDAR and anti-AMPAR encephalitis. These two glutamate receptors mediate the bulk of
excitatory neurotransmission throughout the brain,

3,4

and consequently their loss of function leads

to severe illness. Anti-NMDAR encephalitis is characterized by rapid-onset psychosis, behavioral
and personality changes, memory loss, seizures, and autonomic instability, sometimes
5

progressing to coma and death if left untreated. Patients with anti-AMPAR encephalitis exhibit
6

confusion, agitation, memory loss, and seizures. With immunotherapy, these conditions are
reversible in many patients, though recovery can be a prolonged process and relapses are not
uncommon.

7

Chapter 1 introduces several types of autoimmune-mediated encephalitides of the central
as well as peripheral nervous system. The known mechanisms of pathogenesis among the
xii	
  

described disorders are compared and contrasted. Finally, a number of outstanding questions
about anti-NMDAR and anti-AMPAR encephalitis are posed.
Chapter 2 describes the discovery of several novel features of antibody-mediated
NMDAR dysfunction. First, patient antibodies are likely to cause a loss of function of NMDARs on
all neurons across most brain areas. Both excitatory and inhibitory neurons are susceptible to
antibody-induced receptor loss, and staining of rodent brain sections demonstrates antibody
binding throughout multiple regions, indistinguishable from that of commercially available NMDAR
antibodies directed against GluN1, the obligate NMDAR subunit of the central nervous system.
Second, patient antibodies cause a rapid but saturable decrease in receptor levels. This
loss of surface receptors is paralleled by an increase in the density of internalized receptors,
more of which colocalize with markers of recycling endosomes than with lysosomes. Interestingly,
this pattern of intracellular accumulation is not unique to this pathological event. Stimulation with
NMDA and glycine, and treatment with picrotoxin, both lead to NMDAR internalization into these
compartments in similar proportions.
Third, cross-linking of receptors by patient immunoglobulin is the prominent mechanism
of internalization, and several experiments suggest that this internalization is the likely cause of
NMDAR hypofunction. Patient antibodies do not acutely antagonize receptor function. Neither can
antibodies activate the receptor, which could lead to a homeostatically-driven internalization
process; electrophysiological recordings show no acute potentiation of currents, and
internalization is not dependent on receptor activity.
Finally, patient antibody treatment leads to a compensatory decrease of inhibitory
synapse density onto excitatory neurons, likely to maintain proper excitatory-inhibitory balance in
the face of lowered glutamatergic drive.
In Chapter 3, the cellular and synaptic mechanisms of antibodies from patients with antiAMPAR encephalitis are delineated. First, patient antibodies lead to a selective loss of AMPARs
and resulting synaptic currents from excitatory synapses, and following internalization most of
these AMPARs are degraded in lysosomes.
xiii	
  

Second, commercial antibodies directed against extracellular epitopes do not effectively
cause the internalization of AMPARs that is seen with patient antibodies. One commercial
antibody, if further cross-linked with a secondary antibody, can induce a similar degree of
internalization.
Finally, loss of AMPAR-mediated glutamate transmission by patient antibodies induces
two forms of homeostatic plasticity. Inhibitory synapse density onto excitatory neurons is
decreased, and intrinsic excitability is increased. This increase in excitability allows neurons to
maintain their normal spontaneous firing frequency even in the face of reduced excitatory
synaptic input, although the pattern of firing is altered.
Chapter 4 explores patient antibody effects on intrinsic excitability. This form of
homeostatic plasticity is also detectable after treatment with anti-NMDAR antibodies, though
distinct changes in passive membrane properties underlie the change after AMPAR versus
NMDAR hypofunction. Second, a new model system for continuing our studies of these
encephalitides, organotypic hippocampal slice cultures, is established and the same effects of
patient antibody seen in dissociated neuronal cultures are verified in this more intact system. As
mechanistic understanding of the effects of autoantibodies on receptors deepens, and
subsequent homeostatic processes are uncovered, acute slices and slice cultures will allow for
circuit-level changes mediated by autoantibodies to be linked to cognitive and behavioral
symptoms.
For years, neuroscientists have studied glutamate signaling in the non-human
mammalian brain in an attempt to uncover the link between neuronal function and complex
behavior. Manipulations of NMDARs and AMPARs are especially prominent in the literature, and
the drive to understand the role of these receptors in behavior is further fueled by the number of
neuropsychiatric disorders caused by or linked to mutations in genes that govern excitatory
synapse formation and function. The discovery of a reversible human disease in which
glutamatergic dysfunction causes cognitive and neurological impairments, therefore, becomes an
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important avenue of inquiry, both for improving treatment and recovery for a growing population
of patients, and for contributing to efforts to uncover the biological basis of behavior.
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CHAPTER 1. INTRODUCTION
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Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of
memory, behavior and cognition: insights from molecular, cellular and synaptic
studies
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Abstract
Recently, several novel, potentially lethal and treatment-responsive syndromes that affect
hippocampal and cortical function have been shown to be associated with auto-antibodies against
synaptic antigens, notably glutamate or GABAB receptors. Patients with these auto-antibodies,
sometimes associated with teratomas and other neoplasms, present with psychiatric symptoms,
seizures, memory deficits and decreased levels of consciousness. These symptoms often
improve dramatically after immunotherapy or tumor resection. Here we review studies of the
cellular and synaptic effects of these antibodies in hippocampal neurons in vitro and preliminary
work in rodent models. Our work suggests that patient antibodies lead to rapid and reversible
removal of neurotransmitter receptors from synapses, leading to changes in synaptic and circuit
function that in turn are likely to lead to behavioral deficits. We also discuss several of the many
questions raised by these and related disorders. Determining the mechanisms underlying these
novel anti-neurotransmitter receptor encephalopathies will provide insights into the cellular and
synaptic bases of the memory and cognitive deficits that are hallmarks of these disorders, and
potentially suggest avenues for therapeutic intervention.

2	
  

Introduction
Many encephalitides once considered idiopathic are now thought to be immunemediated. One such disorder predominantly affects structures of the limbic system, including
medial temporal lobes, amygdala, hippocampus, and orbitofrontal cortex.

1-3

As a result, patients

develop short-term memory deficits, emotional and behavioral disturbances such as confusion,
irritability, depression, and sleep disturbances, as well as seizures and sometimes dementia.

2,4

For many years, limbic encephalitis was invariably attributed to the paraneoplastic manifestation
of cancers that express the target neuronal antigen, and the neurological deficits were considered
to be refractory to treatments. These views have changed with the discovery of an expanding
group of encephalitides that occur with or without cancer association, respond to immunotherapy
and range from focal limbic dysfunction to a multi-focal or diffuse encephalopathy. In contrast to
classical paraneoplastic encephalitides in which the target antigens are intracellular and appear
to be mediated by cytotoxic T-cell mechanisms, the novel group of disorders is associated with
autoantigens that are on the cell or synaptic surface and appear to be directly mediated by
antibodies.
The pathogenic role of antibodies can be established using several criteria in vitro and in
vivo. (i) If antigens are membrane proteins, antibodies should have access to and bind
extracellular antigenic epitopes in living cells and ⁄ or tissues. (ii) That antibodies recognize a
particular antigen should be assessed by expressing the antigen in heterologous cells, assayed
by immunostaining or immunoprecipitation followed by Western blotting. (iii) Antibodies cause
structural and ⁄ or functional alterations of the target antigen that can be established in vitro in
dissociated neuron cultures as well as in vivo after antibody infusion. Adjuncts to these
approaches would include using affinity-purified antibody to recapitulate the effects of human
cerebrospinal fluid (CSF) or serum, as well as demonstrating that CSF or serum depleted of the
particular antibody has no structural or functional effects on cells. In the particular case of
antibodies against neurotransmitter receptors or ion channels, receptor ⁄ channel function may be
acutely or chronically altered by antibody treatment, leading secondarily to changes in cellular
3	
  

and ⁄ or synaptic function. (iv) The clinical syndrome should mirror some or all of the phenotypes
of pharmacological or genetic manipulation of the antigen. (v) Passive transfer of disease-specific
antibodies to animals should reproduce the effects of the antibodies on the antigen as well as the
clinical features of the disorder. (vi) Cellular and synaptic alterations, and clinical symptoms,
should improve as antibody titer is reduced. For some autoimmune diseases such as myasthenia
gravis or Lambert–Eaton syndrome, all of these criteria have been met; however, for many, only a
subset have been confirmed (Table 1).
Anti-neurotransmitter receptor limbic encephalitides resemble the autoimmune
syndromes of the neuromuscular synapse (e.g. myasthenia gravis) in that they can also occur
with or without tumor association and are probably antibody-mediated

5-8

(Table 1). However, in

autoimmune synaptic encephalitis the autoantigen is located behind the blood–brain barrier
(BBB), requiring that the antibodies or cells producing antibodies cross this barrier in order to
cause neurological dysfunction (Fig 1). In some disorders the patients’ CSF shows lymphocytic
pleocytosis and intrathecal synthesis of antibodies, suggesting that after initial systemic immune
activation by a tumor or unknown causes, there is an expansion of the immune response within
9

the nervous system. The role of the immune response in the neurological symptoms is further
supported by the correlation between antibody titers and symptoms, and the frequent response of
the disorders to immunotherapies, including plasmapheresis, intravenous Ig, corticosteroids,
cyclophosphamide or rituximab (a monoclonal antibody that depletes B-cells).
The importance of these disorders is that they offer human models of brain–immune
interactions in which the target antigens have critical roles in neuronal synaptic transmission and
plasticity. Therefore, their study will improve our understanding of the effects of the antibodies at
the cellular, synaptic and circuit levels, eventually impacting the clinical management of the
patients. Here we describe the three most recently identified autoimmune synaptic encephalitides
and the state of our understanding of the cellular and synaptic mechanisms, and discuss some of
the many questions raised by these diseases.

4	
  

Anti-NMDA receptor encephalitis
A new, severe, potentially lethal, treatment-responsive disorder, anti-NMDA receptor
encephalitis, was reported recently.

10,11

Patients are usually young women, but also include men,

without a past medical history of interest, who, often after prodromal symptoms of mild
hyperthermia, headache or a viral-like process, develop sudden behavioral and personality
changes for which they are often seen by psychiatrists.

10,11

This clinical presentation is usually

followed by seizures, a decreased level of consciousness, abnormal movements (orofacial and
limb dyskinesias, dystonia, choreoathetosis), autonomic instability (fluctuating blood pressure,
cardiac rhythms and temperature) and sometimes hypoventilation. Magnetic resonance imaging
(MRI) is frequently normal, but in about 40% of patients inflammation is transiently identified in
hippocampus, cerebral or cerebellar cortex, and subcortical regions.

12-16

Patients have serum and

CSF antibodies that react with brain antigens predominantly expressed in the hippocampus.

12

In

two large cohorts comprising 181 patients, including young adults and children, neurologic
improvement was correlated with a decrease in antibody titer.

12,17

Overall, about 75% of the

patients had dramatic or substantial recoveries despite the severity or long duration of symptoms;
19% had partial or limited improvement and 6% died. Analyses of brain biopsies in 14 cases and
autopsy of three patients showed microgliosis, occasional inflammatory B-cell and plasma cell
infiltrates, and very rare T-cell infiltrates, in contrast to other paraneoplastic syndromes in which
cytotoxic T-cell infiltrates are prominent.

18

In the autopsy studies the most prominent microglial

activation was localized in the hippocampus. Most patients with this disorder were previously
categorized as ‘encephalitis of unknown etiology’.

14,19

It is likely that many patients died without a

diagnosis or recovered with empiric treatment with immunotherapy. In fact, the little autopsy
material that is available for analysis comes from cases diagnosed retrospectively using archived
tissue, serum or CSF. The current mortality rate of anti-NMDA receptor encephalitis is
approximately 3%, usually as a result of complications during the stage that patients require
intensive care and ventilatory support.

12,14,17
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When patient antibodies are used to stain rodent brain sections, immunoreactivity is
observed in the neuropil of the hippocampus, with less staining in cortex, striatum and
cerebellum.

12

When used to stain live cultured hippocampal neurons, patient antibodies react with

surface antigens localized to synapses. Additional studies, including immunoprecipitation followed
by mass spectroscopy, led to the identification of the NR1 subunit of the NMDA receptor as the
target autoantigen. NMDA receptors are usually formed from heteromers of two NR1 and two
NR2 subunits.

20,21

There are four NR2 subunits (NR2A–D), which have 50–70% sequence

identity in the extracellular domain; NR1 is ubiquitously distributed in the brain.

22-24

Domain

swapping and other experiments showed that the epitope was located at the N-terminal
extracellular domain of NR1.

12,25

of functional NMDA receptors,

As NR1 is ubiquitously expressed in brain as an obligate subunit

22-24

it remains unclear why patient NR1 antibodies preferentially

label hippocampus rather than all brain regions. This binding pattern may reflect the relatively
high density of NMDA receptors in the hippocampus or a differential post-translational
modification of NR1 in different brain regions.

25

We have recently shown that patients’ antibodies cause a selective, titer-dependent
decrease of NMDA receptor surface density, synaptic localization and currents in vitro, via
antibody-mediated capping and internalization

26

(Fig 2), while overall cellular structure and

synaptic density are largely unchanged. Moreover, these effects are reversible: after 3 days of
treatment with patients’ CSF, followed by 4 days of treatment with control CSF, NMDA receptor
cluster density and synaptic localization recover to levels seen in control cultures. In addition,
NMDA receptor density is dramatically reduced in the hippocampus of rats infused with patients’
antibodies and in the hippocampus of autopsied patients.

26

These studies demonstrated that

patients’ NR1 antibodies reversibly alter the number and distribution of glutamate receptors in
neurons, resulting in a decrease in glutamatergic synaptic function. The lack of neuronal death
and the reversibility of the effects of antibodies on cultured neurons may explain, in part, the
frequent recovery of patients with this disorder. It is unclear, however, whether the prolonged time

6	
  

of recovery (usually several months) represents persistence of the immune response in the brain,
slow recovery of circuit dysfunction caused by the decrease of synaptic NMDA receptors, or both.

Other autoimmune synaptic encephalitides
A goal of ongoing work in our laboratory is to determine whether other syndromes may
involve antibodies to other surface or synaptic antigens. Currently, approximately 90% of patients
with limbic encephalitis of non-viral etiology that we have studied have well-defined immune
responses against neuronal antigens.

27-29

The importance of antibodies to cell surface or synaptic

proteins was shown in a recent study in which these antibodies were found to be more prevalent
than antibodies to intracellular antigens described in paraneoplastic disorders

29

(54 vs. 24%). A

study of 1570 patients with diffuse encephalitis by the California Encephalitis Project showed that
in only 30% could a final diagnosis be established

30

(viral, bacterial, prion, parasitic, fungal). A

pilot study examining a group of cases selected by subphenotype (‘encephalitis, psychosis and
dyskinesias’) showed that 50% had NMDA receptor antibodies.

14

This suggests that other

antibodies to currently unknown antigens may occur in the remaining cases. A second form of
immune-mediated encephalitis in which patients’ serum and CSF antibodies are directed against
AMPA receptors was recently identified.

31

Most patients develop a clinical picture of limbic

encephalitis, including confusion, agitation, seizures and severe short-term memory deficits.
Sometimes patients present with rapidly progressive abnormal behavior that resembles acute
psychosis. Patients are usually women older than 50 years, and 70% had an underlying tumor,
usually lung or breast cancer or tumors of the thymus that express AMPA receptors.
Immunotherapy and treatment of the tumor, if detected, usually results in neurological recovery.
The disorder has a tendency to relapse, and for these patients the outcome depends of how well
each relapse is controlled.
Staining of live cultured hippocampal neurons with patients’ serum or CSF showed that
patient antibodies recognized cell surface antigens that were localized to synapses.
Immunoprecipitation followed by mass spectrometry demonstrated that the target antigens were
7	
  

the GluR1 and ⁄ or GluR2 subunits of the AMPA receptors. AMPA receptors mediate most of the
fast excitatory synaptic transmission in the brain

32

and the majority are heterotetramers

composed of GluR1, 2, 3 or 4 subunits that are expressed in a region-specific manner.
2 and GluR2 ⁄ 3 levels are high in hippocampus and other limbic regions,

34

33

GluR1 ⁄

similar to the

distribution of immunostaining with patients’ antibodies. Preliminary analyses suggest that the
location of the epitope is the N-terminal extracellular domain of these AMPA receptor subunits.

25

None of these patients’ antibodies reacted with GluR3, a subunit identified as an autoantigen in
some patients with Rasmussen’s encephalitis.

35

Treatment of rat hippocampal neurons with patients’ antibodies resulted in a significant
decrease in the synaptic localization of AMPA receptor clusters, without a decrease in overall
synaptic density or NMDA receptor clusters.

31

Moreover, these effects were reversible: after 3

days of treatment with patients’ CSF containing GluR1 ⁄ GluR2 antibodies, followed by 4 days of
treatment with control CSF, AMPA receptor cluster density and synaptic localization recovered to
levels seen in control cultures.

31

A third subtype of autoimmune encephalitis associated with antibodies against the γamino-butyric acid-B (GABAB) receptor was also recently identified.

36

The median age of a cohort

of 15 patients was 62 years (range 24–75); eight were men. All presented with early and
prominent seizures; other symptoms, as well as MRI and electroencephalography findings, were
consistent with predominant limbic dysfunction. Forty seven percent of patients had small cell
lung cancer, and 40% showed propensity to autoimmunity. Cancer screening and demographic
data indicate the disorder also occurs in patients without cancer. Neurological improvement
occurred in 60% of the patients and was correlated with prompt immunotherapy and tumor
control. Staining of live neurons showed	
  that all patients’ serum and CSF had antibodies against
a cell surface antigen. Immunoprecipitation and mass spectroscopy demonstrated that the
autoantigen was the B1 subunit of the GABAB receptor, a metabotropic receptor that when
disrupted causes seizures and memory dysfunction.
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37,38

Three syndromes have been shown to be associated with antibodies against voltagegated potassium channels. Neuromyotonia is a peripheral nervous system disorder characterized
by muscle hyperactivity, while Morvan’s syndrome, in addition to peripheral muscle hyperactivity,
has autonomic and central nervous system manifestations, including insomnia, hallucinations,
anxiety, delirium and memory loss. The third syndrome, limbic encephalitis, consists only of
central nervous system symptoms with no peripheral dysfunction.

39

Similar to the encephalitides

presented above, this type of limbic encephalitis can be paraneoplastic but also more frequently
occurs in the absence of a tumor.

40,41,43

Patients experience psychiatric and neurological

symptoms including short-term memory loss, disorientation, agitation, hallucinations and
seizures, as well as excessive secretions.

40-43

In addition, voltage-gated potassium channel

antibodies have also been reported in patients with isolated seizures and rapidly progressive
dementia, sometimes suggesting a prion disease.

41

A number of other synaptic autoimmune disorders have been identified. These disorders
affect neurological functions other than memory, behavior and cognition, and therefore are only
briefly described here. Two patients with cerebellar ataxia were found to have antibodies against
mGluR1.

44

Autonomic neuropathy, a disorder affecting various autonomic nervous system

functions, can associate with antibodies against ganglionic acetylcholine receptors.

45,46

Patients

with Miller-Fisher syndrome, a variant of Guillain-Barré causing extraocular paralysis, produce
antibodies against ganglioside type GQ1b that cause a complement-mediated block of
neuromuscular transmission.

47

Antibodies against glycine receptors have been reported in one

patient with progressive encephalomyelitis, rigidity and myoclonus, resulting in muscle spasms
and rigidity, facial muscle weakness, and gaze palsies.

48

Although these syndromes are of clinical

interest, the underlying cellular mechanisms remain to be determined.
Although in vitro approaches have been useful to establish the effects of antibodies to
NMDA, AMPA and GABAB1 receptors on neurons and in particular on synapses, in vivo models
will be needed to establish the relationship between the effects of each antibody on synapse and
circuit function, and the changes in behavior, memory and cognition that are hallmarks of these
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disorders. Below we discuss several of the many outstanding questions that, when addressed,
will provide new insights into the basic neuroscience of synaptic plasticity as well as the clinical
understanding of autoimmune encephalitides.

Paraneoplastic and non-paraneoplastic mechanisms of autoimmune synaptic
encephalitides
Anti-NMDA, -AMPA and -GABAB1 receptor encephalitides are often paraneoplastic
syndromes. In this setting, the presence of a tumor that expresses these receptors probably
contributes to breaking immune tolerance. However, other unknown immunological triggers may
be involved, particularly in patients without a tumor. A propensity toward autoimmunity is
suggested by the frequent occurrence of other	
  immune responses, and in the case of anti-NMDA
receptor encephalitis, an apparent predominance in certain ethnic groups (African-American,
Asian, Latin Americans).

14

As in other autoimmune diseases, a number of mechanisms could potentially account for
the immune response in the absence of a tumor. Cross-reactivity of antibodies against different
antigens can occur if the epitopes are sufficiently similar. Guillain-Barré syndrome is an
autoimmune peripheral neuropathy affecting axons and myelin sheaths.
frequently preceded by an infection, often by Campylobacter jejuni.

51-53

49,50

The disorder is

Patients’ serum

antibodies react with peripheral nerve gangliosides as well as lipooligosaccharide from C.
jejuni.

54-56

Other examples include Sydenham’s chorea and systemic lupus erythematosus (SLE).

Sydenham’s chorea is characterized by abnormal movements, hypotonia and neuropsychiatric
symptoms, and characteristically occurs after an infection by group A streptococci.

57,58

Antibodies

from these patients react with gangliosides expressed in the basal ganglia and cross-react with
group A streptococcal N-acetyl-glucosamine.

59-61

In SLE, patients with neuropsychiatric

symptoms and sometimes asymptomatic family members harbor antibodies to double stranded
DNA that also cross-react with a single epitope present in the extracellular region of NR2A and
NR2B of the NMDA receptor.

62,63

10	
  

Given that most paraneoplastic disorders are triggered by small tumors at initial stages of
the disease, it is possible that an immune response resulting in antibody synthesis decreases the
size or eliminates the tumor by antibody binding and complement-mediated cytotoxicity. Thus at
the time of diagnosis, antibodies are present but no tumor is detected. A better understanding of
the events that trigger the immune response in anti-NMDA receptor encephalitis and other
autoimmune encephalitides will be important in both treatment and prevention of these and other
related disorders.

The source and brain access of autoantibodies to synaptic antigens
Two possible, not mutually exclusive, mechanisms that explain the presence of synaptic
autoantibodies in the CNS include passive IgG crossing of the BBB and intrathecal or cerebral
synthesis of antibodies by plasma cells (see Fig 1).
The first possibility is that antibodies synthesized in the periphery cross a pathologically
disrupted BBB, or through regions where the BBB is normally leaky (area postrema) or more
susceptible to systemic changes (e.g. stress, high blood pressure). Several methods for
experimentally increasing BBB permeability have been described in the literature, including focal
ultrasound,

64

hypertonic solute

65,66

and lipopolysaccharide.

models of BBB disruption include peripheral inflammation,

67

More physiologically relevant

68,69

acute stress

70

and epinephrine.

71

Several studies have shown that peripherally administered antibodies can access the brain
following these breaches in BBB integrity. Iodinated antibodies injected into rats were detected in
the brain following osmotic opening of the BBB.

66

Kinoshita et al.

64

showed that focal sonication

caused BBB disruption, allowing intravenously injected dopamine receptor antibodies to enter the
brain and bind to antigen at sites of barrier breakdown.
The second possibility is that antibodies are synthesized intrathecally. Most patients with
anti-NMDA, -AMPA or -GABAB receptor encephalitis have an increased ratio of CSF to serum
IgG concentration, indicating intrathecal synthesis of antibodies. Moreover, protein electrophoretic
analyses of the CSF of these patients often demonstrate multiple distinct bands of IgG that are
11	
  

absent in serum (oligoclonal bands), suggesting the presence of plasma cell clones within the
thecal space that secrete distinct immunoglobulins.

12

Extensive clinical and immunological data

from patients with anti- NMDA receptor encephalitis suggest a model in which both passive
crossing and intrathecal synthesis of antibodies occur. Given that most patients present with
prodromal symptoms (hyperthermia, undetermined viral-like infection) it is likely that the BBB is
transiently disrupted. This is supported by studies showing transient FLAIR (fluid attenuation
inversion recovery) MRI changes involving cortical or subcortical regions. Additionally, after
systemic immune activation by an NMDA receptor-expressing tumor or other unknown factors,
memory B cells that are able to cross a normal BBB will undergo re-stimulation, antigen-driven
affinity maturation, clonal expansion and differentiation into NMDA receptor antibody-secreting
plasma cells. This mechanism, which has been reported in other autoimmune diseases such as
multiple sclerosis,

72

would explain the detection of intrathecal synthesis of antibodies in most

patients with anti-NMDA receptor encephalitis. Moreover, the occurrence of both passive BBB
transfer and intrathecal synthesis of antibodies explains the increasing symptom refractoriness to
predominant serum IgG depleting strategies (intravenous Ig, plasma exchange) during the course
of the disease. Patients who do not respond to these treatments often improve with
cyclophosphamide and rituximab, which are more effective in reducing intrathecal synthesis of
antibodies. A better understanding of the site and dynamics of antibody synthesis during the
course of these disorders is crucial for improving treatment methods and delivery.

Mechanisms underlying antibody pathogenic effects on the target receptors
Several mechanisms may account for the pathogenicity of autoantibodies in autoimmune
encephalitides. These include agonizing or antagonizing the receptor, causing receptor
internalization and degradation resulting in diminished receptor function, or stimulating
complement-mediated neuronal damage. Each of these effects has been demonstrated in
autoimmune diseases of the nervous system, and in some, more than one of these effects
contributes to the disease process.
12	
  

The first possibility is that patient anti-receptor antibodies agonize or antagonize the
receptor. NR2 antibodies from patients with SLE cause neuronal death when injected into mouse
brain; this effect is attenuated by treatment with the NMDA receptor blocker MK-801, suggesting
the antibodies mediate cell death by enhancing channel activation.

62

Conversely, application of

nicotinic acetylcholine receptor (nAChR) antibodies from myasthenia gravis patients to outsideout patches of mouse myotubes caused an acute block of AChR currents that became
irreversible with time.

73

With respect to patient NMDA and AMPA receptor antibodies, there is no

clear evidence supporting direct agonism or antagonism of receptor function. However, the fact
that the epitope for both NMDA receptor and AMPA receptor antibodies is in the N-terminus
raises the possibility that autoantibodies could have direct functional effects. The ligand-binding
domain for both channels is also in the N-terminus, and conformational changes are thought to
couple	
  ligand binding to channel opening.

74,75

Therefore, patient antibodies could sterically hinder

ligand binding or enhance its effects. In addition, N-terminal binding sites for channel modulators
such as zinc and polyamines may be obscured by patients’ antibodies.

76-78

Whole-cell recording

experiments during acute application of antibodies will allow this issue to be resolved.
The second possibility is that patient anti-receptor antibodies cause receptor
internalization and degradation, resulting in diminished receptor function. AChR antibodies from
patients with myasthenia gravis cause a loss of surface receptors by cross-linking and
internalization.

79

Cross-linking and internalization of voltage-gated calcium channels by

autoantibodies has also been shown to occur in patients with Lambert–Eaton syndrome.

80,81

In

anti-NMDA receptor encephalitis, we have shown that the loss of surface NMDA receptors is the
result of antibody-mediated cross-linking and internalization (see Fig 2). Treatment of cultured
neurons with monovalent F(ab) fragments generated from patients’ antibodies did not induce
receptor internalization, but subsequent cross-linking with anti-F(ab) antibodies restored the
decrease caused by intact patient NMDA receptor antibodies.

26

These data demonstrate that

patients’ antibodies produce both structural and functional changes at the synapse. Determining
the range of effects of patients’ antibodies (short-term, long-term and dynamics of recovery) will
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provide insight into the synaptic basis of the memory and behavioral changes seen in these
patients, and help to establish the roles of NMDA receptor signaling in human behavior and
cognition.
The third possibility is that patient anti-receptor antibodies cause complement-mediated
neuronal damage or death. Muscle biopsies from patients with myasthenia gravis have revealed
extensive deposits of components of the complement cascade.

82,83

Autopsy and in vitro studies

have also linked complement activation to Rasmussen’s encephalitis and neuromyelitis optica,
the latter characterized by antibodies to aquaporin-4.

84-86

IgG1 and IgG3, subclasses of IgG

capable of activating complement, are the main IgG types of NMDA and AMPA receptor
antibodies. In anti-NMDA receptor encephalitis, we have not found evidence of deposits of
complement in autopsies of patients. In light of the substantial recoveries made by many of these
patients, extensive neuronal damage due to complement activation seems unlikely. Furthermore,
it is unclear whether the elements of the complement cascade that are present in the central
nervous system are sufficient to induce complement-mediated lysis. Further studies are needed
to determine the degree of involvement of complement-mediated mechanisms in the brain and
tumors of patients with synaptic autoimmune encephalitis.

Homeostatic compensatory changes in response to antibody-mediated decreases of
receptor levels
Compensatory mechanisms at the cellular and synaptic level have been shown to occur
in autoimmune disorders of the nervous system in humans and in experimental model systems.
Studies from mouse models of myasthenia gravis and patients’ tissue have shown an enhanced
rate of synthesis of AChRs and increased expression levels of the α, β, δ and ε subunits of the
AChR, as well as increased acetylcholine release upon stimulation.

47,87-89

Purkinje cells treated

with IgG from patients with Lambert-Eaton syndrome show a loss of P ⁄ Q-type	
  voltage-gated
calcium channel currents and a concomitant increase in R-type currents.

90

Deletion of the α-1a

subunit of the P ⁄ Q-type channel in mice causes age-related ataxia and muscle weakness and
14	
  

results in enhanced L- and N-type calcium channel currents in Purkinje cells.

91

These

observations raise the possibility that homeostatic mechanisms occur in anti-NMDA receptor and
anti-AMPA receptor encephalitis, although this remains to be demonstrated. Support for this idea
comes from the changes in synaptic strength observed after pharmacological blockade of
glutamate receptors. Several studies have shown that, after 48 hours of NMDA or AMPA receptor
blockade, miniature excitatory postsynaptic current (mEPSC) amplitude is enhanced.

92,93

Effects of maternal antibodies on fetal development and subsequent behavior
Although the symptoms of anti-NMDA receptor encephalitis are largely similar between
children and adults, children tend to have less severe autonomic problems and increased speech
dysfunction.

17,94

These differences, along with a subset of patients who were diagnosed during

pregnancy, raise questions about the effects of anti-receptor antibodies on the developing brain,
and the long-term consequences of fetal or pediatric exposure to the antibodies.
Several other autoimmune diseases are associated with abnormalities in offspring.
Children born to mothers with SLE, especially male children, have higher rates of developmental
and learning disabilities than children born to unaffected mothers.

95,96

In mice, in utero exposure

to antibodies from SLE patient serum results in morphological and behavioral abnormalities in
offspring.

97

Maternal myasthenia gravis is often associated with arthrogryposis multiplex

congenita, a condition caused by lack of fetal movements that is associated with joint
contractures and muscle weakness in offspring.

98

Interestingly, asymptomatic women who have

children with this condition may harbor anti-AChR antibodies. Serum from these women contains
antibodies only to a fetal subunit of the AChR, and is therefore specifically harmful to the fetus
rather than the mother.

99,100

These studies highlight the devastating effects that maternal

autoantibodies can have on fetal development.	
  	
  
Studies of mothers of autistic children also raise the possibility that maternal antibodies
may impact fetal development. Several studies of these women have suggested that they harbor
anti-neuronal antibodies in their serum, although the antigen(s) is unknown. For example, serum
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from a woman with an autistic child and a child with a severe language disorder contained
antibodies that bound rodent neurons and caused behavioral and motor abnormalities in mice
exposed to the serum as embryos.

101

In addition, serum from mothers with autistic children

caused hyperactivity and stereotypic behavior in rhesus monkeys exposed prenatally to the
serum.

102

These results show that asymptomatic women may have circulating neuronal

antibodies that have access to the fetal brain and may affect brain development.
Two women who developed anti-NMDA receptor encephalitis at 14 and 17 weeks of
pregnancy, when the specific transplacental transfer of IgG1 and IgG3 is not yet fully developed,
delivered apparently normal newborns. Studies performed in one of the babies showed a lack of
antibodies in serum and CSF.

103

However, given the importance of synaptic activity, in particular

glutamatergic and GABAergic transmission during neural circuit development,	
  in utero exposure
to antibodies from patients with anti-NMDA receptor encephalitis, or other autoimmune
encephalitides, may potentially affect normal fetal brain development, resulting in neurological
and behavioral disturbances in offspring. Thus, establishing a mechanistic link between antireceptor antibodies, access to the developing brain, effects on synapses and circuits and
ultimately behavior, assayed across a life span, will be important for resolving these issues in a
broad spectrum of disorders.

Relating the effects of synaptic receptor antibodies to neurological symptoms
Glutamate binding to NMDA receptors and AMPA receptors is crucial for synaptic
transmission and plasticity. Pharmacological blockade or genetic reduction of these receptors has
been shown to alter learning and memory and other behaviors in animal models.

104-111

The

balance between excitatory and inhibitory synaptic inputs is also altered, and this has been
shown to affect circuit function and behavior.

112-118

In addition, NMDA

119-126

and ⁄ or AMPA

127-131

receptor hypofunction has been proposed to be part of the pathophysiological mechanisms
underlying schizophrenia.
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It is interesting to consider why patients with anti-NMDA receptor antibodies develop a
complex syndrome that includes psychosis, learning and memory dysfunction, abnormal
movements, autonomic instability and frequent hypoventilation, whereas those with AMPA
receptor antibodies preferentially develop psychiatric and amnestic symptoms. Studies using
genetic deletions of NMDA or AMPA receptor subunits in mouse models provide some insight
into this issue. Whereas NR1 knockout mice die shortly after birth due to hypoventilation,
with spatially restricted NR1 deletion can survive into adulthood.

133

132

mice

CA1- specific NR1 knockouts

have impaired spatial and temporal memory and a loss of CA1 long-term potentiation (LTP).

134

Mice with an inducible, reversible knockout of NR1 in forebrain show impairment in the
maintenance of long-term memory if NR1 expression is turned off during the memory storage
phase.

135

In addition to memory deficits, targeted manipulation of NR1 expression can result in

schizophrenia-like symptoms. Hypomorphic expression of NR1 leads to increased stereotypic
behavior and decreased sociability, while early postnatal loss of NR1 in a subset of cortical and
hippocampal interneurons results in decreased pre-pulse inhibition and increased social isolationinduced anxiety.

108,136

Moreover, subanesthetic doses of NMDA receptor blockers such as

phencyclidine and ketamine are psychotomimetic, and they recapitulate many of the positive and
negative signs of schizophrenia in humans and rodents as well as repetitive orofacial movements,
autonomic instability and seizures.

137-139

The remarkable similarity between these phenotypes,

the effect of patients’ antibodies resulting in a dramatic decrease of synaptic NMDA receptor
clusters and function, and the reduced levels of NMDA receptors in autopsied patients support an
antibody-mediated pathogenesis of anti-NMDA receptor encephalitis, and strengthen the NMDA
receptor hypofunction hypothesis of schizophrenia.

136

The consequences of loss of AMPA receptor expression have also been studied in
mouse models. Spatial learning and memory are largely unaffected in GluR1 knockout mice
despite the fact that LTP is reduced in CA1 and CA3

140

and working memory is diminished.

141,142

GluR2 knockout mice show reduced exploration and impaired motor coordination. In these
animals, AMPA receptor-mediated synaptic transmission is reduced, but LTP is enhanced.
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143,144

GluR2 knockout mice also have increased cell death,

145,146

possibly due to excitotoxicity related

to increased, compensatory insertion of GluR1 homomeric AMPA receptors. Although AMPA
receptor subunit knockout mice have not provided a satisfying explanation for the role of AMPA
receptors in synaptic plasticity related to learning and memory, the fact that patients with AMPA
receptor antibodies have short-term learning and memory deficits argues that further studies at
the circuit and behavioral levels are warranted.
GABAB1 receptor knockout mice display a variety of neurological and behavioral
abnormalities, including spontaneous seizures, enhanced anxiety, hyperactivity, hyperalgesia and
impaired memory,

37,38

suggesting dysfunction of the limbic system. Consistent with these

experimental data, patients with anti-GABAB1 receptor antibodies present with an encephalitis
that associates with early and prominent seizures, confusion, agitation, behavioral problems and
severe short-term memory deficits along with MRI abnormalities predominantly involving the
hippocampi. Interestingly, both GABAB1 receptor knockout mice and mice treated with a GABAB1
receptor antagonist, CGP56433A, exhibit antidepressant-like behavior in a forced swim test and a
learned helplessness paradigm,

147,148

suggesting that GABA signaling may have disparate effects

on different aspects of mood such as depression and anxiety. Combined with animal studies,
these patients can provide rich insight into the role of GABAB1 receptor signaling in memory,
behavior and cognition.
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Conclusions
We have begun to obtain a better cellular- and synaptic-level understanding of a new and
remarkable group of immune-mediated behavioral and memory disorders. On the clinical side, we
would like to know the frequency of these antibodies in patients with milder or form frustes of the
syndromes (e.g. predominant psychosis, isolated refractory seizures), and whether the effects of
antibodies on glutamate and GABA receptors, and synapses, vary according to different
subgroups of patients, improving the diagnostic and treatment strategies. It is likely that the
effects of antibodies on children (or antibody effects on immature hippocampal synapses) are
different from those on adults (or on mature hippocampal synapses), and this may account for
some of the behavioral differences between adults and children. Another critical issue is the
optimal type of immunotherapy at different stages of the disease, and the duration of treatment. In
current clinical practice, most patients receive intravenous immunoglobulins, plasma exchange
and corticosteroids as the first line of therapy. When these fail, rituximab (a B-cell-depleting
monoclonal antibody) and cyclophosphamide are increasingly being used in an attempt to modify
the levels of antibodies behind the BBB. However, it is unclear whether or how these treatments
modify the effects of antibodies on synapses.
On the basic neuroscience side, a major goal will be to develop and test rodent models in
a battery of behavioral tests designed to assay hippocampal, amygdala, cortical and cerebellar
function in each disorder. In this way, we can begin to relate the cellular, synaptic and circuit
effects of patients’ antibodies to behavioral deficits in learning, memory, and other cognitive and
motor manifestations.
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Figure 1. Mechanisms involved in the presence of antibodies in the central nervous
system.
(A, B) In a subset of anti-NMDA receptor encephalitis patients, an immune response is initiated
against neuronal antigens expressed by an ovarian teratoma or another tumor (A). In another
subset of patients, the immunological trigger is unknown (B). The ectopic expression of NMDA
receptors by a tumor or other mechanisms (e.g. molecular mimicry) breaks down immune
tolerance by a sequence of events including antigen presentation by T or dendritic cells
generating memory B cells (1) and antibody-producing plasma cells (2). Systemically synthesized
antibodies can bind to NMDA receptors present in the tumor and behind a disrupted or leaky
blood–brain barrier (BBB) (4). Disruption of the BBB is likely to occur early in the disease
process. In addition, memory B cells (probably also activated T cells) that are able to cross a
normal BBB (5) will undergo re-stimulation (resident antigen presenting cells or T cells, 6),
antigen-driven affinity maturation, clonal expansion and differentiation into NMDA receptor
antibody-secreting plasma cells (7). Antibodies produced within the CNS by plasma cells (8) or
reaching the CNS by BBB disruption (4) bind to extracellular epitopes of NMDA receptor (9)
causing subsequent internalization (see Fig 2).
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Figure 2. Mechanisms underlying cellular and synaptic effects of anti-NMDA receptor
antibodies.
(A) AMPA and NMDA receptors are localized in the postsynaptic membrane and are clustered at
the postsynaptic density. (B) Patient antibodies in the central nervous system bind selectively to
NMDA receptors at the synapse as well as extrasynaptic receptors. This binding leads to receptor
cross-linking. (C) NMDA receptors that have been bound and cross-linked by antibodies are
internalized, resulting in a decrease of surface NMDA receptors. Other synaptic components,
21	
  

such as postsynaptic AMPA receptor clusters, PSD-95, as well as presynaptic terminals, dendrite
branches, dendritic spines and cell viability, are unaffected. Thus patient anti-NMDA receptor
antibodies lead to a rapid, selective loss of NMDA receptors from neuronal membranes. This
effect is titer-dependent and reverses after antibody titers are reduced (not shown). (D, E) Rodent
cultured neurons treated with control or patient CSF for 3 days, and subsequently stained for NR1
to label NMDA receptor clusters, vGlut to label presynaptic sites and PSD-95 as a postsynaptic
marker. Note that patient CSF causes a decrease in dendritic NR1 cluster density, while vGlut
and PSD-95 cluster density remains unchanged. (F, G) Whole-cell patch-clamp recordings of
miniature excitatory postsynaptic currents (mEPSCs), which consist of a fast AMPA receptormediated component and a later, slower NMDA receptor-mediated component that is APV
sensitive. Compared with neurons incubated with control CSF (F), those treated with CSF from a
patient with NMDA receptor antibodies show a selective loss of the APV-sensitive NMDA receptor
component (G).
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Table 1: Immune-mediated disorders of the synapse
Antigen

Syndrome/
symptoms

Patient
antibody
effects on
receptors

Criteria

Clinical
references

Molecular
references

Decreased
synaptic
NMDARs;
decreased
NMDARmediated
mEPSCs

1-4, 6

Dalmau et
al., 2007

Dalmau et al.,
2008;
Hughes et al.,
2010

Decreased
synaptic
AMPARs;
decreased
AMPARmediated
mEPSCs

1-3, 6

Lai et al.,
2009

Lai et al.,
2009

Pending
characterization

1-2, 4

Lancaster
et al., 2009

NMDAR
agonism

1, 3, 5

Brey et al.,
2002

DeGiorgio et
al., 2001;
Kowal et al.,
2006

1, 2, 4,
(5 only
features of
neuromyo
-tonia), 6

Vincent et
al., 2004

Kleopa et al.,
2006;
Shillito et al.,
1995;
Rho et al.,
1999

Central nervous system disorders
NR1 subunit
of NMDA
receptor

GluR1/2
subunit of
AMPA
receptor

GABAB1
receptor

NR2A/
NR2B
subunits of
NMDA
receptor

Voltagegated K+
channel

Anti-NMDA
receptor
encephalitis ⁄
psychosis,
behavioral and
memory deficits,
dyskinesias,
language
reduction (in
children),
seizures,
autonomic
instability
Anti-AMPA
receptor
encephalitis ⁄
short-term
memory deficits,
seizures,
psychiatric
manifestations;
tendency to
relapse
Anti-GABAB1
receptor
encephalitis ⁄
seizures, shortterm memory
deficits
Neuropsychiatric
systemic lupus
erythematosus ⁄
cognitive deficits,
psychosis,
memory deficits,
mood disorder,
seizure, headache
Neuromyotonia,
limbic
encephalitis,
Morvan’s
syndrome ⁄ muscle
spasticity,
memory deficit,
insomnia,
hallucinations
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Peripheral nervous system disorders
Nicotinic
acetylcholine
receptors

Myasthenia gravis/
muscle weakness,
fatigue

Decreased
synaptic
AChRs at
neuromuscular
junctions;
decreased
AChRmediated
currents

1-6

Dau et al.,
1977;
Meriggioli
and
Sanders,
2009

Voltage2+
gated Ca
channel

Lambert–Eaton
syndrome ⁄ muscle
weakness

Decreased
presynaptic
channels at
neuromuscular
junctions;
decreased
neurotransmitter
release

1-6

Leys et al.,
1989;
Motomura
et al.,
2000;
Pourmand,
2009

Ganglionic
nicotinic
acetylcholine
receptor

Peripheral
neuropathy,
autonomic
nervous system
dysfunction

Reduction in
AChR current
due to antibody
cross-linking

1-6

Vernino et
al., 1998,
2000
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Toyka et al.,
1975;
Lennon et al.,
1985;
Missias et al.,
1997;
Jahn et al.,
2000; Leite
et al., 2008;
Lang &
Vincent, 2009
Fukunaga et
al., 1983;
Lang et al.,
1983;
Takamori et
al., 2000;
Kim, 1985;
Molenaar,
2008; Nagel
et al., 1988;
Peers et al.,
1993; Pinto et
al., 2002
Xu et al.,
1999;
Vernino et al.,
2004, 2008;
Wang et al.,
2007
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Abstract
Objective: A severe but treatable form of immune-mediated encephalitis is associated
with antibodies in serum and cerebrospinal fluid (CSF) against the GluN1 subunit of the N-methylD-aspartate receptor (NMDAR). Prolonged exposure of hippocampal neurons to antibodies from
patients with anti-NMDAR encephalitis caused a reversible decrease in the synaptic localization
and function of NMDARs. However, acute effects of the antibodies, fate of the internalized
receptors, type of neurons affected, and whether neurons develop compensatory homeostatic
mechanisms were unknown and are the focus of this study.
Methods: Dissociated hippocampal neuron cultures and rodent brain sections were used
for immunocytochemical, physiological, and molecular studies.
Results: Patient antibodies bind to NMDARs throughout the rodent brain, and decrease
NMDAR cluster density in both excitatory and inhibitory hippocampal neurons. They rapidly
increase the internalization rate of surface NMDAR clusters, independent of receptor activity. This
internalization likely accounts for the observed decrease in NMDAR-mediated currents, as no
evidence of direct blockade was detected. Once internalized, antibody-bound NMDARs traffic
through both recycling endosomes and lysosomes, similar to pharmacologically-induced NMDAR
endocytosis. The antibodies are responsible for receptor internalization, as their depletion from
CSF abrogates these effects in hippocampal neurons. We find that although anti-NMDAR
antibodies do not induce compensatory changes in glutamate receptor gene expression, they
cause a decrease in inhibitory synapse density onto excitatory hippocampal neurons.
Interpretation: Our data support an antibody-mediated mechanism of disease
pathogenesis driven by immunoglobulin-induced receptor internalization. Antibody-mediated
down-regulation of surface NMDARs engages homeostatic synaptic plasticity mechanisms, which
may inadvertently contribute to disease progression.
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Introduction
Glutamatergic transmission is central to many functions thought to depend on synaptic
plasticity, including learning and memory, cognition, and behavior.

1,2

Several newly described

immune-mediated encephalitides that target synaptic antigens have offered novel insights into the
link between synapse function and human cognition and behavior.

3,4

One form of autoimmune

encephalitis is associated with antibodies against the N-methyl-D-aspartate receptor (NMDAR).

5,6

Consistent with the prominent role of NMDARs in glutamatergic transmission as well as activity
dependent plasticity, symptoms of anti-NMDAR encephalitis include sudden behavioral, memory,
and personality changes that progress to seizures, autonomic instability, and coma. If left
untreated, irreversible deficits and death can occur. Immunotherapy treatment leads to a
substantial to full recovery for about 80% of patients.

7

NMDARs, along with a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and
kainate receptors, mediate glutamatergic synaptic transmission and have a prominent role in
synaptic plasticity, learning, and behavior. Pharmacological blockade or genetic reduction of
NMDARs alters learning and memory,

8–10

excitatory–inhibitory balance,

11,12

and behavior.

13–15

Defects in glutamate signaling have been linked to neuropsychiatric disorders, and NMDAR
hypofunction has been proposed to be part of the pathophysiological mechanisms underlying
schizophrenia.

16

Subanesthetic doses of NMDAR blockers such as phencyclidine and ketamine

are psychotomimetic in humans and rodents, and cause the stereotypic movements, autonomic
instability, and seizures that are characteristic of anti-NMDAR encephalitis.

17,18

The striking parallels between patient symptoms and the consequences of NMDAR
hypofunction described above underscore the importance of determining the mechanisms of
antibody-mediated dysfunction in this disease. Patient antibodies cause a selective, reversible
decrease of NMDAR surface density, synaptic localization, and currents in vitro.

6,19,20

Here, we

explored mechanisms of disease pathogenesis, investigating whether patient antibodies
preferentially bind to NMDARs on specific types of neurons or brain regions, the time course of
receptor internalization, whether antibodies directly antagonize the receptor, whether components
38	
  

besides immunoglobulins within patient cerebrospinal fluid (CSF) can contribute to downregulation of NMDARs, and whether neurons engage homeostatic mechanisms in response to
the decrease in glutamatergic transmission. Understanding the acute mechanisms of antibodymediated dysfunction sets the stage for future studies in in vivo models of anti-NMDAR
encephalitis.
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Materials and Methods
Cell culture and treatment
Hippocampal neurons were prepared and maintained from embryonic day 18 rat pups as
previously described.

19

Neurons were treated on in vitro day 14 (DIV14; unless otherwise noted)

with CSF from patients or controls at a dilution of 1:20, and drugs at the following concentrations:
amino-phosphonovaleric acid (APV), 50µM; picrotoxin, 10µM; NMDA, 1mM; glycine, 10µM.
Cerebrospinal fluid and serum were obtained from randomly selected patients with wellcharacterized clinical manifestations of anti-NMDAR encephalitis. Antibodies to the NMDAR were
6

demonstrated as previously reported. Control samples were obtained from patients undergoing
CSF screening for various disorders not associated with antibodies against the NMDAR.

Immunostaining
Immunostaining protocols for cultured neurons and rodent brain sections have been described in
detail elsewhere.

19

Neurons were treated as specified in the text and incubated with the following

primary antibodies: to label NMDARs, anti-GluN1 (Millipore, Billerica, MA; AB9864R, 1:100) and
anti-GluN1 (Sigma, St Louis, MO; G8913, 1:100); inhibitory neurons, anti–glutamic acid
decarboxylase 6 (GAD6; Developmental Studies Hybridoma Bank, Iowa City, IA; 1:20; the
monoclonal antibody was developed by Dr David I. Gottlieb at Washington University School of
Medicine and is maintained at the University of Iowa); presynaptic terminals, anti-bassoon
(Stressgen Bioreagents, Ann Arbor, MI; VAM-PS003, 1:400); recycling endosomes, anti-Rab11
(Zymed Laboratories, San Francisco, CA; 71–5300, 1:100); lysosomes, anti-Lamp1 (Enzo Life
Sciences, Plymouth Meeting, PA; ADI-VAM-EN001, 1:100); amino-butyric acid receptors
(GABAARs), anti-GABAAβ2/3 (Millipore, 05–474, 1:500); and presynaptic inhibitory terminals, antivesicular GABA transporter (vGAT; Synaptic Systems, Gottingen, Germany; 131-004, 1:1,000).
Manufacturer’s websites provide controls for specificity of all primary antibodies used. Omission
of primary antibodies was used as a control for each of the secondary antibodies, which were
raised in goat against rabbit, mouse, or guinea pig immunoglobulin G (IgG) and conjugated to
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various Alexa Fluor dyes. All secondary antibodies were obtained from Invitrogen (Carlsbad, CA).
Coverslips were mounted and imaged on a confocal microscope (Leica, Wetzlar, Germany; TCS
SP5) and analyzed using interactive software (custom-written ImageJ macros).

19

To selectively

label internalized NMDARs, surface NMDARs were bound by incubation with patient CSF (1:20).
After treatment, coverslips were incubated with unconjugated goat anti-human secondary
antibody at 1:10. Then, neurons were fixed, permeabilized, and stained with fluorescently
conjugated goat anti-human secondary antibody, which only labeled internalized receptors due to
the saturation of surface receptors by unlabeled antibody. To label surface and internal receptors,
after incubation with patient antibodies, the remaining surface antibody-bound receptors were
labeled with a fluorescent secondary antibody. Neurons were fixed, permeabilized, and stained
with a different secondary antibody against human IgG to label the internalized antibody-bound
receptors, as well as anti-GluN1 to label the total population of NMDARs. To induce NMDAR
internalization pharmacologically, we used 2 different treatment protocols. The first was a 24-hour
incubation with picrotoxin, which blocks inhibitory GABAAR-mediated synaptic transmission,
causing a homeostatic decrease of NMDARs.

21

The second was a 15-minute exposure to NMDA

plus glycine, which activates the NMDAR and causes rapid internalization.

22

Electrophysiology
Electrophysiology protocols have been described in detail elsewhere.

19

Whole cell voltage clamp

recordings were made from DIV17–21 neurons that had been treated for 30 minutes with patient
or control CSF, or 24 hours with patient F(ab) fragments. Extracellular physiological solution was
(in millimolars): 119 NaCl, 5 KCl, 2 CaCl2, 30 glucose, 10 HEPES, pH=7.4. For excitatory
currents, intracellular pipet solution was (in millimolars): 100 cesium gluconate, 0.2
ethyleneglycoltetraacetic acid (EGTA), 5 MgCl2, 2 adenosine triphosphate, 0.3 guanosine
triphosphate, 40 HEPES, pH=7.3. For inhibitory currents, intracellular solution was (in
millimolars): 140 KCl, 2 MgCl2, 11 EGTA, 10 HEPES, 7 glucose, pH=7.3. Tetrodotoxin (TTX)
(1µM) was used to block action potentials, picrotoxin (10µM) was used to block GABAAR41	
  

mediated miniature inhibitory postsynaptic currents (mIPSCs), cyanonitroquinoxaline-dione
(CNQX) (10µM) was used to block AMPAR-mediated miniature excitatory postsynaptic currents
(mEPSCs), and APV (50µM) was used to block NMDAR-mediated mEPSCs. Spontaneous
miniature postsynaptic currents were detected and analyzed using MiniAnalysis (Synaptosoft,
Leonia, NY). NMDAR and AMPAR components of mEPSCs were separated temporally by their
distinct kinetics. The amplitude of the NMDAR-mediated current was determined in a window
between 15 and 25 milliseconds after the peak of the averaged AMPAR-mediated component,
which has a fast, <1-millisecond rise time.

19

F(ab) fragment preparation
F(ab) fragments were prepared from patients’ serum whole IgG using a kit according to the
manufacturer’s directions (Pierce Fab Micro Preparation Kit; Thermo Scientific, Waltham, MA).	
  	
  

	
  
Immunodepletion
Patient CSF was incubated on 50:50 Protein A and rProtein G agarose column (Invitrogen)
equilibrated in binding buffer (0.01M sodium phosphate, pH=7.0, 0.15M sodium chloride). The
column was rocked for 1 hour at room temperature, and CSF was collected and stored at -20°C
until use.

Statistical analysis
Data sets were analyzed using a Mann-Whitney U test or one-way analysis of variance test.
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Results
Patient and commercial GluN1 antibodies were similarly distributed after immunostaining
Patient antibodies stained rat hippocampus in sections more intensely than other brain
6

regions, such as cortex, striatum, and hindbrain. To determine whether this pattern was due to a
modification of the epitope specific to the hippocampus, or due to a higher expression of
NMDARs within the hippocampus, we asked whether the staining pattern of patient antibodies
was the same as that of 2 commercially available antibodies that recognize epitopes within the
intracellular, C-terminal domain of GluN1.
Staining with commercial antibodies produced the same enrichment in hippocampal
immunoreactivity as patient CSF (Fig 1A). Patient and commercial antibodies both stained cortex,
striatum, and cerebellum as well as hippocampus, although less intensely. The difference in
overall staining intensity between the sample on the left (Patient 1) and on the right (Patient 2) is
due to a difference in the patients’ antibody titers. Double labeling with patient and commercial
antibodies showed their considerable colocalization in the dendritic layers of the dentate gyrus
(see Fig 1B). These results suggest that the observed preferential hippocampal staining of patient
antibodies is due to a higher density of NMDARs within the hippocampus compared with other
regions.

Patient antibodies decreased surface NMDARs on excitatory and inhibitory hippocampal neurons
We asked whether the effects of patient antibody treatment differed between excitatory
and inhibitory neurons, potentially disrupting the excitatory–inhibitory balance, as occurs following
administration of some NMDAR antagonists that cause symptoms similar to anti-NMDAR
encephalitis.

11,23

Cultured hippocampal neurons were treated with control or patient CSF, then

stained for surface NMDARs, total GluN1, and GAD6 to label inhibitory neurons. Inhibitory
neurons were identified by strong immunoreactivity of GAD6 in cell bodies.
In excitatory, GAD-negative neurons, patient CSF treatment caused a significant
decrease in surface NMDAR cluster density compared with control CSF (Fig 2). A similar result
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was seen in inhibitory, GAD-positive neurons. Patient antibodies also caused a decrease in the
intensity of surface NMDAR clusters. There was no difference in the density of surface NMDAR
clusters recognized by patient antibodies in these two populations of neurons in control
conditions. Thus, there is a lack of regional or neuronal subtype specificity in the binding and
effects of patient antibodies, suggesting broad actions of anti-NMDAR antibodies on cell types
across brain regions.

Patient antibodies increased the rate of NMDAR internalization in a time-dependent and
activity-independent manner
We next wanted to study the time course and dynamics of NMDAR internalization.
Hippocampal neurons were treated with patient antibodies or patient F(ab) fragments (previously
19

shown not to decrease surface NMDAR clusters ) for 15 minutes to 48 hours. Surface NMDAR
cluster density was significantly decreased compared with F(ab) treatment after 12 hours of
exposure to patient antibodies (Fig 3A, B). There was no further reduction with longer treatment.
The accumulation of internalized NMDAR clusters followed the same time course, also reaching a
maximum by 12 hours of treatment.
We next examined whether internalization was stimulated by any mechanism other than
antibody-mediated cross-linking. For example, activation of glutamate receptors can prime them
for internalization.

22

Agonism by patient antibodies could decrease surface NMDAR levels by

similar mechanisms. This could change our understanding of the effects of patient antibodies on
NMDARs, and point to new options for patient care. To test this possibility, hippocampal neurons
were treated with control or patient CSF with or without APV, an NMDAR blocker, then stained for
surface NMDARs, bassoon (for presynaptic terminals), and total GluN1.
As expected, patient CSF caused a significant decrease in synaptic NMDAR clusters
(see Fig 3C, D). This effect was not mitigated by the presence of APV, demonstrating that
antibody-mediated internalization was independent of NMDAR activity and did not occur as a
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compensatory response to agonism of the receptor. Therefore, the mechanism of internalization
is likely due primarily to the effects of NMDAR cross-linking by patient antibodies.

Patient antibody-bound receptors trafficked through recycling endosomes and lysosomes
In anti-NMDAR encephalitis, NMDARs are bound by immunoglobulins during
endocytosis, a scenario that would not occur under physiological conditions of receptor
internalization. To examine whether intracellular NMDAR trafficking was influenced by this unique
situation, we compared patient antibody treatment with 2 pharmacological manipulations that
caused NMDAR internalization, picrotoxin (a GABAAR blocker) and NMDA/glycine.
Hippocampal neurons were treated with one of the following: patient CSF for 24 hours,
patient F(ab) fragments for 24 hours, F(ab) fragments plus picrotoxin for 24 hours, or F(ab)
fragments for 24 hours plus NMDA/glycine for 15 minutes (see Materials and Methods). F(ab)
fragments allowed us to track NMDAR internalization induced by pharmacological treatment,
without the complication of full patient immunoglobulin (IgG) further stimulating endocytosis (see
Fig 3A, B). Following treatment, neurons were stained for internalized NMDARs, and Rab11 and
Lamp1, markers for recycling endosomes and lysosomes, respectively.
Patient CSF, picrotoxin, and NMDA/glycine all caused a significant increase in NMDAR
internalization compared with F(ab) fragments alone (Fig 4). Between the 3 conditions that
promoted internalization, there was no significant change in the proportion of internalized
NMDARs that localized to recycling endosomes or lysosomes. Additionally, for all 3 conditions, a
greater percentage of internalized receptors colocalized with recycling endosomes than
lysosomes. These data suggest that the post-endocytic trafficking of NMDARs is not affected by
IgG binding the receptor.
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Patient CSF caused NMDAR hypofunction through immunoglobulin-induced receptor
internalization
Patient antibodies could potentially modulate receptor function independently of their
ability to internalize NMDARs because the epitope is within the N-terminus of GluN1,

24

a region

that also contains the ligand binding domain. To test this possibility, we first performed whole-cell
patch-clamp recordings of mEPSCs from hippocampal neurons on DIV17–21 that had been
treated with control or patient CSF for 30 minutes, a time point before significant internalization of
NMDARs has occurred (see Fig 3A, B). NMDAR-mediated current amplitudes from neurons
treated for only 30 minutes with patient CSF were not significantly different from current
amplitudes in neurons treated with control CSF (Fig 5). Consistent with this finding, we also
observed that exposure for 24 hours to F(ab) fragments, which were incapable of triggering
receptor internalization (see Fig 3A, B), did not result in a significant decrease in NMDARmediated current amplitude. Both of these findings were in contrast to the large reduction in
NMDAR-mediated mEPSC amplitude that resulted from 24 hours of treatment with patient CSF,

19

and provide physiological evidence to support the notion that antibody-mediated NMDAR
hypofunction results from receptor internationalization and not an acute antagonism of receptor
function.
We next asked whether other factors within patient CSF, such as cytokines or
complement components, were necessary for NMDAR internalization. We previously
demonstrated that IgGs from patient serum and CSF were sufficient to decrease NMDAR cluster
density,

19

but whether they were also necessary to do so remained unknown. Hippocampal

neurons were stained with IgG-depleted patient CSF to confirm complete depletion, then treated
with control CSF, patient CSF, or IgG-depleted CSF, and stained for surface and total NMDARs
and bassoon.
Depleted CSF did not retain immunoreactivity on hippocampal neurons, indicating that
IgGs were successfully depleted from the samples (Fig 6). Unlike patient CSF, treatment with
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depleted CSF did not reduce NMDAR cluster density, demonstrating that in the absence of IgG,
patient CSF no longer caused NMDAR internalization.
These data show that the removal of patient antibodies from CSF abrogates both
neuronal staining and the effects of patient CSF on surface NMDAR density. Together with
previous experiments using purified IgG from patient CSF,

19

these results demonstrate that

immunoglobulins within patient CSF are both necessary and sufficient to cause the loss of
surface NMDARs.

Patient antibodies caused homeostatic plasticity of inhibitory synapse density but not gene
expression
We next assessed whether homeostatic plasticity mechanisms were engaged after
patient antibody-induced NMDAR internalization. We verified that we were able to detect
homeostatic plasticity in our hippocampal cultures using a pharmacological blocker of NMDARs,
APV, which had previously been shown to elicit an increase in surface NMDAR levels.

25

Hippocampal neurons were treated for 24 hours with APV, then stained for surface and total
NMDARs and bassoon.
In contrast to patient CSF, which caused a significant decrease in synaptic NMDAR
cluster density (Fig 7A, C), APV treatment resulted in a significant increase. This confirmed that
homeostatic plasticity was detectable in our experimental system.
Similar to APV treatment, neurons may attempt to increase NMDAR insertion in response
to patient antibodies. This would be undetectable due to antibody-mediated internalization of any
newly inserted receptors. Alternatively, neurons may up-regulate NMDAR transcription after
internalization. Many genes are transcriptionally regulated by activity,
homeostatic plasticity are transcription-dependent.

27

26

and some forms of

To evaluate this possibility, quantitative

polymerase chain reaction was performed to determine the levels of NMDAR subunit mRNA
following patient antibody or APV treatment for 24 hours, but no changes were detected in GluN1,
GluN2A, or GluN2B, or in any of the GluN1 C-terminal splice variants (data not shown). We also
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measured transcriptional changes in these splice variants after 7 days of treatment, but mRNA
levels were still unchanged (data not shown).
We next assayed whether inhibitory synapses displayed homeostatic plasticity in
response to the NMDAR hypofunction caused by patient antibodies. Evidence suggests a link
between NMDAR dysregulation and impairments in inhibition,

28,29

for example, the frequent

occurrence of seizures in encephalitis patients that is indicative of defects in inhibitory tone.
Hippocampal neurons were treated on DIV17–20 with control or patient CSF for 24 hours, then
whole cell patch clamp recordings of mIPSCs were made. Neither the amplitude nor the
interevent interval of mIPSCs was changed by patient CSF treatment (see Fig 7C, D; p>0.05).
Gene expression of GAD1 and GAD2, enzymes responsible for GABA production in inhibitory
neurons, was also unchanged (data not shown).
Finally, we treated hippocampal neurons on DIV14 with control or patient CSF for 24
hours, then fixed and stained for the inhibitory GABAAR and inhibitory presynaptic marker vGAT.
We found that patient antibody treatment caused a significant decrease in inhibitory synapse
density (see Fig 7B, D) onto excitatory neurons, which were identified by a lack of vGAT staining
within the cell body. Together, our data show that although loss of NMDARs does not stimulate
transcriptional changes of NMDAR subunits or splice variants, neurons are able to partly adjust
their inhibitory tone in a compensatory direction.
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Discussion
This study revealed several novel findings related to the effects of antibodies from
patients with anti-NMDAR encephalitis, including the lack of neuron subtype specificity, time
course of the effects, fate of internalized receptors, and homeostatic responses to NMDAR loss.
In addition, the results confirmed that the major mechanism of dysfunction was loss of NMDARs
due to IgG-mediated internalization, which likely occurs throughout the brain. The process of
internalization plateaued after 12 hours, reaching a steady state that persisted throughout
the duration of treatment. This may reflect the presence of a population of NMDARs unaffected
by antibodies, or represent a state of equilibrium between the rate of internalization and the rate
of receptor insertion into the plasma membrane.
Internalization of NMDARs can be promoted by receptor activity.

22,30

We were unable to

block patient antibody-mediated NMDAR internalization with APV, suggesting that patient
antibodies did not exert activity-dependent effects. Electrophysiological analyses also excluded
direct blockade as a prominent mechanism of antibody-mediated NMDAR hypofunction. These
results, along with the finding that patient F(ab) fragments did not cause internalization and that
patient IgG was necessary and sufficient for internalization, suggested that antibody-mediated
NMDAR internalization was solely due to cross-linking of the receptors. A similar mechanism had
been demonstrated for myasthenia gravis and Lambert–Eaton syndrome.

31

Moreover, human

autopsy studies of anti-NMDAR encephalitis patients showed deposits of IgG and decreased
NMDARs, without evidence of cytotoxic T-cell mechanisms, all supporting an antibody-mediated
pathogenesis.

5,32

NMDARs dynamically traffic into and out of the synapse during physiological processes,
1

such as synapse maturation and synaptic plasticity. This cycling is largely governed by
regulatory signals within the C-terminal portions of the receptor complexes that mediate clathrindependent endocytosis.

33–35

We showed that internalized, antibody-bound receptors entered a

recycling and a degradation pathway, although the proportion of internalized receptors in
recycling compartments consistently exceeded that within lysosomes. Even with different
49	
  

manipulations to induce NMDAR internalization, the trajectory of post-endocytic trafficking was
unchanged, excluding an immunoglobulin-specific effect.
Homeostatic plasticity is important for maintaining the stability of neuronal network
activity in the face of potentially destabilizing changes in the strengths of individual synapses.

36

The NMDAR hypofunction in anti-NMDAR encephalitis led us to the question of whether patient
antibody treatment can induce homeostatic changes in cultured neurons. We did not detect gene
expression changes in any NMDAR subunits with either APV or patient antibody treatment,
concluding that transcriptional regulation was not a major locus of homeostatic plasticity in this
system.
We noted the similarity in some symptoms between anti-NMDAR encephalitis and
schizophrenia. Several lines of evidence in animal models and humans had led to the hypothesis
that NMDAR hypofunction in inhibitory interneurons led to disinhibition in corticolimbic regions,
underpinning core symptom domains in schizophrenia.

16,37

We examined whether patient

antibodies may have had disparate effects on excitatory and inhibitory neurons, but these
populations of neurons were indistinguishable by our analyses.
Inhibitory neurons exert complex control over excitatory cell firing, both because of their
exuberant connectivity (in cortex, a single interneuron can contact more than half of the local
pyramidal neurons) and because of the diverse effects they have on neuronal spiking, depending
38

on the location of the synaptic connections (axon initial segment, distal dendrites, soma, etc).

Therefore, even a small change in the magnitude of connectivity could have profound effects on
network excitability and precision. We found that although neither expression of the GABA
synthesizing enzymes, GAD1 and GAD2, nor amplitude and interevent interval of mIPSCs was
changed by patient CSF treatment, GABAergic synapse density onto excitatory neurons was
decreased. We suspect this difference in results between the electrophysiology and staining
experiments was due to the increased power of immunostaining experiments, which sampled ~30
neurons per condition, as opposed to the physiology experiments, which measured mIPSCs from
6 neurons per condition.
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This was consistent with literature showing that genetic or pharmacological NMDAR
dysfunction can lead to a loss of inhibitory tone, but indicated a distinct mechanism that may
contribute in this disease. Although a loss of glutamatergic drive to inhibitory interneurons is often
considered the pathogenic event leading to disinhibition in NMDAR hypofunction models, our
data suggested that an additional phenomenon could be the homeostatic down-regulation of
inhibitory synapses onto excitatory neurons.
It will be important to extend these findings to an in vivo context to establish the
pathophysiological mechanisms leading to dysfunction in patients. However, it is interesting to
consider the implications of engaging homeostatic plasticity mechanisms in the presence of antiNMDAR antibodies. Examples of homeostatic responses to altered levels of activity have been
found or hypothesized to occur in several neurological disorders, including epilepsy, myasthenia
gravis, Alzheimer’s disease, and schizophrenia.

39

In schizophrenia, and NMDAR hypofunction

models, loss of inhibition may contribute to symptom profile and disease progression.
Understanding the mechanisms that drive circuit-level changes underlying the behavioral and
neurological symptoms of the disorder will be important to link the pathophysiologic events of
anti-NMDAR encephalitis with those of other disorders with similar neuropsychiatric
manifestations.
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Figure 1: Patient and commercial GluN1 antibodies were similarly distributed after
immunostaining.
(A) Sagittal mouse brain sections immunostained for GluN1 with 2 patient CSF samples (top) or 2
commercial anti-GluN1 antibodies against C-terminal epitopes (bottom). The pattern of NMDAR
localization was similar, with the greatest intensity of immunoreactivity in the hippocampus and
less in cortex, striatum, and cerebellum. Scale bar = 1 mm
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(B) Cellular localization in hippocampal dentate gyrus neurons stained with patient CSF (left,
green in overlay) or commercial anti-GluN1 (middle, red in overlay), demonstrating co-labeling of
NMDAR clusters throughout the neuropil. Scale bar = 20 µm.
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Figure 2: Patient antibodies decreased surface NMDARs on excitatory and inhibitory
hippocampal neurons.
(A, B) Hippocampal neurons immunostained for surface GluN1, total GluN1, and GAD-6 after
treatment for 24 hours with control or patient CSF and imaged with confocal microscopy. A,
GAD-, excitatory neurons; B, GAD+, inhibitory neurons. Surface NMDARs were defined as the
colocalization of non-permeabilized patient antibody staining, which recognized an extracellular
epitope, and permeabilized commercial GluN1 staining, which recognized an intracellular epitope.
Scale bar = 5 µm.
(C) Quantification of surface NMDAR density on excitatory, GAD- neurons, and inhibitory, GAD+
neurons (n=12-28 cells per condition, 3 independent experiments). Treatment with patient CSF
caused a similar, significant reduction in surface NMDAR clusters on both excitatory and
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inhibitory neurons compared to control CSF treatment (excitatory, 27.97±2.67 versus 13.71±2.51;
inhibitory, 26.38±1.96 versus 15.6±1.83). Asterisk indicates significance; one-way ANOVA,
p<0.05.
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Figure 3: Patient antibodies increased the rate of NMDAR internalization in a timedependent and activity-independent manner
(A) Hippocampal neurons were treated for various lengths of time with patient CSF or F(ab)
fragments and then immunostained for surface antibody-bound GluN1, internalized antibodybound GluN1, and total GluN1. F(ab) fragments were used to monitor the constitutive, antibodyindependent turnover of NMDARs. Coverslips were imaged and NMDAR cluster density
analyzed. Scale bar = 5 µm.
(B) Quantification of surface and internalized NMDARs following treatment (n=17-55 cells per
condition). Surface NMDAR density was significantly decreased after 12 hours of patient CSF
treatment compared with patient antibody-derived F(ab) fragments (86.02±7.46% versus
140.2±8.68%), after which surface levels reached a plateau. This was paralleled by an increase
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over time in the density of internalized NMDARs (by 12 hours, 72.01±9.67% versus
17.83±4.26%). Asterisk indicates significance; one-way ANOVA, p<0.05.
(C) Hippocampal neurons were treated for 24 hours with control or patient CSF with or without
APV, then immunostained for surface GluN1, total GluN1, and presynaptic terminal marker
bassoon. Scale bar = 5 µm.
(D) Quantification of synaptic NMDAR density (n=12-18 cells per condition, 3 independent
experiments). Patient CSF caused a significant reduction in NMDAR density in both the
presence (46.86±4.17% of control CSF) and absence (52.18±6.19% of control CSF) of APV.
Asterisk indicates significance; one-way ANOVA, p<0.05.
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Figure 4: Patient antibody-bound NMDARs trafficked through recycling endosomes and
lysosomes.	
  
(A) Hippocampal neurons were treated with one of the following: F(ab) fragments generated from
patient antibodies, patient CSF (full IgG), F(ab) plus NMDA and glycine, or F(ab) plus picrotoxin.
Neurons were then immunostained for internalized antibody-bound GluN1, Rab11 (to mark
recycling endosomes), and Lamp1 (to mark lysosomes). Scale bar = 5 µm.
(B) Quantification of intracellular trafficking of NMDARs following treatment (n=15-19 cells per
condition, 3 independent experiments). Left, quantification of internalized NMDAR clusters
following treatment; middle, quantification of internalized NMDAR clusters colocalized with
recycling endosome marker Rab11; right, quantification of internalized NMDAR clusters
colocalized with lysosome marker Lamp1. After 24 hours, there was a significant increase in
internalized NMDAR cluster density following treatment with patient CSF, F(ab) plus NMDA and
glycine, and F(ab) plus picrotoxin compared with F(ab) fragments alone (5.26±0.45, 5.40±1.31,
6.15±1.03 versus 0.68±0.17; p<0.05). Asterisk indicates significance; one-way ANOVA, p<0.05.
There were no significant differences in the intracellular localization of NMDARs between the
three treatments used to induce internalization (recycling endosomes: 29.56±4.54%,
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32.46±4.37%, 47.83±6.01%; lysosomes: 12.03±2.80%, 10.16±2.25%, 17.21±8.12%). One- way
ANOVA, p>0.05.
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Figure 5: Patient antibodies did not acutely antagonize the NMDAR
(A) Representative traces of AMPAR- and NMDAR-mediated miniature excitatory postsynaptic
currents (mEPSCs) from whole-cell patch-clamp recordings of hippocampal neurons following
treatment with control or patient CSF for 30 minutes or F(ab) fragments for 24 hours. Recordings
were made in the presence of TTX, picrotoxin, and 0 mM Mg

2+

to isolate dual glutamatergic

currents. In the lower traces, APV was added to block the NMDAR-mediated portion of the
mEPSC.
(B) Representative averaged NMDAR-mediated mEPSCs recorded from neurons in different
treatment conditions. The difference between the 0 mM Mg

2+

condition and the 0 mM Mg

2+

plus

APV condition is plotted, showing the NMDAR current.
(C) Quantification of NMDAR current amplitude following treatment (n=5-10 cells per condition).
Amplitude was not significantly different (2.14±0.62 pA, control CSF; 1.26±0.34 pA, patient CSF;
1.79±0.55 pA, F(ab) fragments). One-way ANOVA, p>0.05.
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Figure 6: Patient antibodies were directly pathogenic.
(A) IgGs were removed from patient CSF with protein A- and protein G-agarose beads.
Hippocampal neurons were immunostained with control CSF, patient CSF or IgG-depleted CSF.
Similar to control CSF, depleted CSF did not stain neurons. Scale bar = 20 µm.
(B) Hippocampal neurons were treated for 24 hours with control CSF, patient CSF, or depleted
CSF, then immunostained for surface GluN1, total GluN1, and bassoon. Scale bar = 5 µm.
(C) Quantification of synaptic NMDAR density following treatment (n=19-21 cells per condition, 3
independent experiments). Depletion of IgG from patient CSF abrogated the reduction in synaptic
NMDAR cluster density (depleted CSF, 99.15±6.47% of control CSF; patient CSF, 57.70±7.10%
of control CSF). Asterisk indicates significance; one-way ANOVA, p<0.05.
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Figure 7: Patient antibodies caused a homeostatic decrease of inhibitory synapse density
(A) Hippocampal neurons were treated for 24 hours with control CSF, patient CSF, or APV, then
immunostained for surface GluN1, total GluN1, and bassoon. Scale bar = 5 µm.
(B) Quantification of synaptic NMDAR density following treatment (n=18-20 cell per condition, 3
independent experiments). Patient CSF caused a significant decrease in cluster density
(43.27±4.48 % of control CSF), while APV caused a significant increase (160.4±12.69 % of
control CSF). Asterisk indicates significance; one-way ANOVA, p<0.05.
(C) Representative traces of GABAAR-mediated miniature inhibitory postsynaptic currents
(mIPSCs) from whole-cell patch-clamp recordings of hippocampal neurons following treatment
with control or patient CSF for 24 hours. Recordings were made in the presence of TTX, CNQX,
and APV.
(D) Quantification of mIPSC amplitude and inter-event interval following treatment (n=5-6 cells
per condition). Amplitude (45.49±6.97 pA, control CSF; 40.74±3.43, patient CSF) and inter-event
interval (1734±474.1 ms, control CSF; 1139±154.3 ms, patient CSF) were not significantly
different. Mann-Whitney test, p>0.05.
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(E) Hippocampal neurons were treated with control or patient CSF for 24 hours, then
immunostained for GABAAR and vGAT. Scale bar = 5 µm.
(F) Quantification of inhibitory synapse density onto excitatory neurons following treatment (n=30
cells per condition, 3 independent experiments). Patient CSF caused a significant decrease in
inhibitory synapse density (87.52±3.00% of control treatment). Asterisk indicates significance;
Mann-Whitney test, p<0.05.
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Abstract
Objective: Autoimmune mediated anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR) encephalitis is a severe but treatment-responsive disorder with prominent
short-term memory loss and seizures. The mechanisms by which patient antibodies affect
synapses and neurons leading to symptoms are poorly understood.
Methods: The effects of patient antibodies on cultures of live rat hippocampal neurons
were determined with immunostaining, Western blot and electrophysiological analyses.
Results: We show that patient antibodies cause a selective decrease in the total surface
amount and synaptic localization of GluA1- and GluA2-containing AMPARs, regardless of
receptor subunit binding specificity, through increased internalization and degradation of surface
AMPAR clusters. In contrast, patient antibodies do not alter the density of excitatory synapses, Nmethyl-D-aspartate receptor (NMDAR) clusters or cell viability. Commercially available AMPAR
antibodies directed against extracellular epitopes do not result in a loss of surface and synaptic
receptor clusters, suggesting specific effects of patient antibodies. Whole-cell patch clamp
recordings of spontaneous miniature postsynaptic currents show that patient antibodies decrease
AMPAR-mediated currents, but not NMDAR-mediated currents. Interestingly, several functional
properties of neurons are also altered: inhibitory synaptic currents and vGAT staining intensity
decrease, while the intrinsic excitability of neurons and short interval firing increase.	
  
Interpretation: These results establish that antibodies from patients with anti-AMPAR
encephalitis selectively eliminate surface and synaptic AMPARs, resulting in a homeostatic
decrease in inhibitory synaptic transmission and increased intrinsic excitability, which may
contribute to the memory deficits and epilepsy that are prominent in patients with this disorder.
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Introduction
There are several recently identified paraneoplastic autoimmune encephalitides in which
patients develop autoantibodies against cell surface and synaptic proteins,

1,2

including NMDARs

3

(Dalmau et al., 2007; Dalmau et al., 2008) and AMPARs. Patients with anti-AMPAR encephalitis
have anti-GluA1 and/or anti-GluA2 antibodies in serum as well as cerebrospinal fluid (CSF).
These patients mainly present with limbic dysfunction including confusion, agitation, seizures, and
severe short-term memory deficits, which recover with interventions to reduce antibody titer. In
3

spite of effective treatments, there is a high rate of relapse, and the cellular and synaptic
mechanisms that underlie these syndromes are largely unknown. AMPARs are heterotetramers
composed of a combination of subunits, GluA1-4, that are expressed in a region-specific
manner

4–8

9

and mediate most of the fast excitatory synaptic transmission in the brain. Though

AMPARs are widely expressed throughout the central nervous system, GluA1/2 and GluA2/3
levels are exceptionally high in the hippocampus and other limbic regions,

10

similar to the

3

distribution of immunoreactivity with patient antibodies. AMPARs are essential for basal
excitatory transmission as well as expression of long-term potentiation,

11–13

a process linked to

memory formation. Our previous studies showed that patient antibodies caused a decrease in the
3

synaptic localization of AMPAR clusters. However, how patient antibodies alter synaptic and
neuronal function underlying patients’ symptoms is poorly understood. Moreover, genetic
manipulations eliminating individual AMPAR subunit expression and thus function result in only
limited deficits in memory tasks,

11,12,14

inconsistent with the complete loss of short-term memory

seen in patients. Recent work suggests that the total surface expression of AMPAR proteins,
regardless of subunit type, is important for LTP expression.

13

Whether patient antibodies cause a

decrease of surface AMPAR protein is not known.
Here we report that patient anti-AMPAR antibodies decrease surface protein level and
synaptic localization of AMPARs, regardless of receptor subunit binding specificity, without
dismantling excitatory synapses. Interestingly, the loss of AMPAR-mediated synaptic
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transmission results in a compensatory decrease of inhibitory synaptic transmission and an
increase in intrinsic excitability.
Together, these changes may contribute to the loss of memory and seizures that are
hallmarks of this disorder in patients.
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Materials and Methods
Cell culture and patient antibody treatment
Primary rat hippocampal neuron and astrocyte co-cultures were prepared from embryonic day 1819 as previously described.

15,16

Patient or control CSF was collected and filtered using Millex

filters (Millipore). High-titer CSF was diluted 1:20-100 to treat neurons in vitro for 24 hours or as
stated. Immunoglobulin G (IgG) from one patient’s (02-066) serum was collected and filtered
using protein A/G sepharose columns as described.

16

Treatment with patient IgG (~20 µg/ml) or

serum (1:200 dilution) decreased synaptic AMPAR clusters to a similar extent as treatment with
CSF (see Results), without side effects to culture health. Patient CSF was used to treat neurons
unless otherwise stated. In surface biotinylation experiments, control or patient sera were used to
treat neurons (1:200 dilution). Each CSF was tested for antibody reactivity by staining mouse or
rat brain sections and HEK cells expressing GluA1/GluA2 heteromers of the AMPAR as
previously described.

3

Patient samples
Control patients were from a previously described tissue bank (Lai et al., 2009): 07-238, 09-724,
09-726. All patients had idiopathic non-inflammatory neuropsychiatric symptoms, without
autoantibodies in serum and CSF. Anti-AMPAR encephalitis patients: 04-067, 02-066, 09-276.
Case 04-067 is patient #1, Case 02-066 is patient #2 described in previously published work.

3

Case 04-067 is GluA1 positive, GluA2 and GluA3 negative; Case 02-066 is GluA2 positive, GluA1
and GluA3 negative. Case 09-276 (not previously reported) is GluA1 positive, GluA2 and GluA3
negative. This patient is a 46 year-old woman who 4 years ago developed a clinical picture of
typical paraneoplastic limbic encephalitis associated with breast cancer. She was treated with
tumor resection, immunotherapy and chemotherapy and had a remarkable response to treatment.
She is back to work, although has mild residual memory problems.	
  Table 1 shows the usage of
patient samples in experiments.
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Biotinylation of surface proteins and analysis by western blot
Neurons were treated with patient serum with anti-GluA1 or anti-GluA2 antibodies for 1 day.
Procedures for total, intracellular, and surface protein collection were performed as described
previously.

16

Briefly, neuron cultures were washed with PBS-based rinsing buffer and incubated

for 30 min at 4°C with 1 mg/ml Sulfo-NHS-Biotin (Thermo Fisher Scientific) in rinsing buffer.
Neurons were then lysed in RIPA buffer (150mM NaCl, 1mM EDTA, 100mM Tris-HCl, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, pH=7.4), supplemented with 1:500 protease
inhibitor mixture III (Calbiochem) at 4°C for 1 h. Lysates were cleared of debris by centrifugation
at 12,4000g for 20 minutes. An aliquot of the supernatant was taken for the total protein, and a
second aliquot was incubated with avidin-linked agarose beads (Immobilized Monomeric Avidin;
Thermo Fisher Scientific) overnight at 4°C to absorb surface fraction. After centrifugation, the
supernatant was removed for the intracellular fraction. The beads were subsequently washed and
eluted for surface protein. Protein samples were separated on 4-15% SDS-PAGE gel and
transferred to nitrocellulose membranes. Surface fractions were probed with antibodies against
GluN1 (rabbit, 1:1000, Chemicon AB1516; replaced by Millipore AB9864, similar results obtained
with both), GluA1 (rabbit, 1:200, Millipore AB1504), GluA2/3 (rabbit, 1:200, Chemicon AB1506),
Stargazin (rabbit, 1:500, Millipore AB9876), GABAB1Rs (guinea pig, 1:200, Millipore AB2256),
GABAARβ2/3 (mouse, 1:200, Millipore 05-474), vGAT (guinea pig, 1:1000, Synaptic Systems
131-004), and β-actin (chicken, 1:1000, Abcam ab13822). Intracellular fractions were used to
probe for intracellular GluA1, GluA2/3, actin and vGAT. Total lysate protein fractions were used to
probe for total GluA1. MAP2, actin and GABAARs were used as loading controls for intracellular,
total and surface fractions, respectively. Blots were incubated with alkaline phosphatase (AP)conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (1:3000, Cell Signaling), and
signals were visualized using Western-Star chemiluminescent detection system (Applied
Biosystems). All quantified images were in the linear exposure range, were digitally scanned in
ChemiDoc™ XRS+System (Bio-Rad) and signals quantified using Image Lab™ software (BioRad).
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Whole cell electrophysiological recordings
Whole-cell voltage clamp recordings were performed from 17–21 div hippocampal pyramidal
neurons at room temperature (22-25°C), using a HEKA EPC 10 patch clamp amplifier and
Patchmaster multi-channel data acquisition software. Briefly, neurons were incubated in
extracellular physiology solution (in mM): for miniature excitatory or inhibitory postsynaptic
currents (mEPSCs or mIPSCs), recordings were performed in 119 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2,
30 glucose, 10 HEPES, pH=7.4; NMDAR-mediated mEPSCs recordings were performed with 0
MgCl2 and 1 glycine; action potential recordings were performed in 140 NaCl, 3 KCl, 0.6 MgCl2,
2.5 CaCl2, 10 HEPES, 10 glucose. Voltage-clamp recordings were made using borosilicate glass
microelectrodes (resistance 4-6 MΩ) filled with intracellular solution (in mM): mEPSCs recording
was performed with 100 cesium gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES,
pH=7.2; mIPSCs and action potential recording were performed with 140 KCl, 2 MgCl2, 11 EGTA,
10 HEPES, 7 glucose, pH=7.3. mEPSCs and mIPSCs were recorded at -70 mV in the presence
of combinations of the following drugs to isolate desired currents: TTX (1 µM), Picrotoxin (10 µM),
APV (50 µM) and CNQX (10 µM). Action potentials were recorded in current clamp mode. Pipette
voltage offset was neutralized before the formation of a gigaohm seal. Membrane resistance,
series resistance, and membrane capacitance were determined from current transients elicited by
a 5 mV depolarizing step from a holding potential of -80 mV, using the whole-cell application of
Patchmaster software. Criteria for cell inclusion in the data set included a series resistance ≤30
MΩ and stability throughout the recording period. Currents were amplified, and sampled at 20
kHz, then miniature current recording traces were digitally low-pass filtered at 2.5 kHz and events
were detected and analyzed using MiniAnalysis (Synaptosoft, Leonia, NY).

Immunostaining for surface AMPARs, pre- and postsynaptic components
To stain surface AMPAR clusters, control or treated neurons were washed in culture media and
were incubated with commercial anti-GluA1 (rabbit, 1:10, Calbiochem PC246; immunogen is a
synthetic peptide (RTSDSRDHTRVDWKR) corresponding to amino acids 271-285 of rat GluA1),
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or anti-GluA2 (1:500, Millipore MAB397; immunogen is recombinant fusion protein with putative
N-terminal portion of GluA2 from AA 175-430) antibodies directed against an extracellular epitope
for 30 minutes, washed and incubated with appropriate fluorescently conjugated secondary
antibodies for 30 minutes, and washed in PBS. Neurons were then fixed in 4%
paraformaldehyde/sucrose in PBS for 15 minutes, permeabilized with cold 0.25% Triton X-100 for
5 minutes, and blocked in 5% normal goat serum (Invitrogen) for 1 hour at room temperature.
Additional immunostaining was performed with various combinations of primary antibodies: antiGluN1 (rabbit, 1:1000, Chemicon AB1516; replaced by Millipore AB9864, similar results obtained
with both), anti-GluA1 against an intracellular epitope (rabbit, 1:200, Millipore AB1504), antiGluA2/3 (rabbit, 1:100, Millipore AB1506), anti-PSD-95 (mouse, 1:500, Fisher Thermo Scientific
MA1-045), anti-Stargazin (rabbit, 1:500, Chemicon AB9876), anti-SV2 (mouse, 1:200,
Developmental Studies Hybridoma Bank), anti-VGLUT1 (guinea pig, 1:5000, Chemicon AB5905).
Antibodies were visualized after staining with the appropriate fluorescently conjugated secondary
antibodies (1:200, Jackson ImmunoResearch or Invitrogen). To pulse label surface AMPAR and
chase the subsequent internalization, neurons were incubated with commercial anti-GluA1
(rabbit, 1:100, Calbiochem) antibodies for 2 hours. This antibody does not induce significant
reduction of surface AMPARs (Fig 4). After 2 hours, unbound antibodies were washed off and
neurons were treated with control or patient CSF for 24 hours. Remaining surface AMPARs were
labeled live with conjugated secondary antibodies. In experiments measuring internalized
AMPAR clusters, remaining surface AMPAR epitopes were pre-blocked by non-fluorescence antirabbit secondary antibodies (0.2mg/ml, Jackson ImmunoResearch).

17

After fixation and

permeabilization, internalized AMPARs were visualized by applying fluorescently conjugated
secondary antibodies.

Confocal imaging, image analysis and statistical analysis
Randomly selected hippocampal pyramidal neurons, identified by morphology (Hughes et al.,
2010; Peng et al., 2012) were confocally imaged (Leica TCS 4D system). Images were
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thresholded automatically using an iterative thresholding technique (Bergsman et al., 2006), and
the number and area of individual immunostained pre- or postsynaptic clusters were determined
using interactive software (custom-written ImageJ macros). Clusters with pixel overlap of pre- and
postsynaptic markers were considered colocalized and thus synaptic. Cluster density was
compared among conditions using the Kruskal-Wallis nonparametric ANOVA test followed by
Dunn’s pairwise multiple comparison test, unless otherwise indicated. All values are presented as
mean ± s.e.m.
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Results
Patient anti-GluA1 or GluA2 antibodies decrease surface AMPAR protein and synaptic
localization
Previous work showed that anti-AMPAR encephalitis patients had antibodies against
3

GluA1 and GluA2 in their CSF. Since some patients with autoimmune encephalitis had
antibodies against multiple antigens,

3,18

we selected patients with only GluA1 or GluA2 antibodies

in order to eliminate effects from other antibodies. To further confirm the specificity of antibody
binding, we incubated patient CSF with control human embryonic kidney (HEK) 293 cells or cells
expressing GluA1/GluA2-containing AMPARs to deplete these specific antibodies. The control
3

depleted patient CSF still stained neuronal surface AMPAR clusters as previously reported while
patient CSF depleted by incubation with GluA1/GluA2 expressing HEK cells showed little
immunostaining (Fig 1A). This result confirms that patient antibodies in CSF samples are
predominantly anti-GluA1/GluA2 antibodies.	
  	
  
Previous work showed that the antibodies from a single patient with anti-AMPAR
encephalitis selectively decreased synaptic AMPAR clusters, and after antibody removal, AMPAR
3

clusters density recovered back to control levels. Patients with anti-AMPAR encephalitis could
be subdivided into two groups depending on the specificity of the antibodies present in the patient
CSF (GluA1 or GluA2). Previous studies knocking out the expression of GluA1 or GluA2 AMPAR
subunits suggested that there could be compensatory expression of the other remaining
subunits.

11,12,14

We investigated whether patient anti-GluA1 or anti-GluA2 antibodies had similar

effects on the localization of AMPAR subunits. Specifically, we assessed whether anti-GluA1
patient antibodies affected just GluA1-containing AMPARs or both GluA1 and GluA2-containing
AMPARs. Hippocampal neurons were incubated for 1-3 days with patient CSF containing antiGluA1 or anti-GluA2 antibodies, followed by immunocytochemical analyses of synaptic and
surface GluA1 or GluA2/3 clusters.
Patient anti-GluA1 and anti-GluA2 antibodies significantly decreased both GluA1- and
GluA2/3-containing synaptic AMPAR cluster density (Fig 1B, C). Similar results were obtained
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using purified IgG prepared from the same patient samples, suggesting that the patient antibodies
alone caused the decrease of synaptic AMPAR cluster density. In addition, patient antibodies
also decreased the size and fluorescence intensity of AMPAR clusters (Fig 1D), suggesting that
antibodies also cause de-clustering. Furthermore, surface biotinylation followed by western blot
analysis of GluA1 or GluA2 subunits showed a decrease of surface protein levels of both GluA1
and GluA2, treated by either anti-GluA1 or anti-GluA2 patient CSF (Fig 1F, G), compared to CSF
from control patients. Western blots from treated and control neurons showed that the amount of
intracellular AMPARs was not different and thus the total amount of AMPARs decreased (Fig 1F,
G), consistent with degradation of internalized receptors (see Fig 3). However, there was neither
a significant compensatory increase in GluA2/3-containing receptors within synapses (Fig 1B-E),
nor of surface or intracellular GluA2/3 protein levels (Fig 1F, G) when treated with anti-GluA1
patient antibodies or vice versa. These data suggest that patient antibodies directed against
either subunit have similar effects on GluA1- and GluA2-containing AMPARs, the main subunits
comprising AMPARs in hippocampus.

6,10

Patient antibodies do not alter glutamatergic synapse density and cell viability
Because AMPARs interact with many other synaptic proteins and are major components
of mature synapses,

8,19

we examined whether patient anti-AMPAR antibodies also affected

excitatory synapse density and/or the density of other postsynaptic components. Hippocampal
neurons were cultured with CSF or serum containing anti-GluA1 or anti-GluA2 antibodies for 1-3
days, followed by immunostaining or western blot analyses of synaptic proteins, including
presynaptic vesicular glutamate transporter (vGlut), postsynaptic PSD-95, the AMPAR interacting
protein Stargazin,

20,21

the NMDAR obligate subunit GluN1, inhibitory GABAA receptor (GABAAR)

and GABAB1 receptors (GABAB1R). Patient antibodies did not alter the density of excitatory
synapses (Fig 2C), presynaptic vGlut clusters, postsynaptic PSD-95, GluN1 or Stargazin clusters,
compared to control CSF (Fig 2A, C, D), or the amount of surface GluN1, Stargazin or GABAB1R
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protein (Fig 2B, E). These data suggest that patient anti-AMPAR antibodies do not significantly
alter the major components of synapses.	
  	
  
To examine whether the patient antibodies affected neuronal viability, the density of
neurons on coverslips was assayed by staining with DAPI and microtubule associated protein 2
(MAP2) to label nuclei and neuronal dendritic arbors, respectively. After 24 hours of treatment,
the density of neurons treated with patient CSF was comparable with the density in control or
untreated conditions (Fig 2F), suggesting that patient anti-AMPAR antibodies did not cause
significant neuronal loss. Consistently, the percentage of TUNEL-positive apoptotic neurons was
very low (<1%) in all conditions (Fig 2G), suggesting that patient anti-AMPAR antibodies did not
induce significant neuronal apoptosis. This is consistent with the lack of significant neuronal loss
and frequently observed patient recovery to pre-disease baseline.

3

Together, our data suggests that the loss of surface and synaptic localization caused by
patient antibodies was specific to AMPARs, without widespread effects on most other synaptic
components or neuronal viability.

Patient antibodies increase the net internalization of AMPAR clusters
The decrease of synaptic AMPARs following patient antibody treatment was
accompanied by the appearance of AMPAR-positive clusters that were non-synaptic (Fig 1A,
green GluA1 or GluA2 clusters that were not colocalized with red PSD-95 clusters in patient
antibody treatment, compared to yellow clusters in control treatment). To determine whether the
reduction of surface AMPARs resulted from receptor internalization, surface AMPARs were
labeled by a commercial anti-GluA1 antibody (comGluA1), followed by treatment with control or
patient CSF for 1, 4 and 24 hours.
Control treated neurons showed a decrease of surface GluA1 AMPARs by 24 hours (Fig
3A, C). This suggested that under basal conditions, GluA1-containing AMPARs undergo a
relatively slow rate of turnover. In contrast, neurons treated with patient CSF showed a
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significantly decreased surface cluster density by 24 hours (Fig 3A, C). This suggests that patient
anti-AMPAR antibodies cause a rapid internalization of surface AMPARs.
To specifically quantify internalized AMPARs, neurons were pre-treated with an excess of
unconjugated secondary antibodies (Fig 3A, bottom image shows effectiveness of pre-blockade).
The total number of internal GluA1-containing AMPARs decreased in control treated neurons
over time, but increased in neurons treated with patient antibodies at 1 hour and 4 hours,
consistent with induced internalization of AMPARs (Fig 3B, D). By 24 hours, internal GluA1
clusters were low in both conditions (Fig 3B, D), indicating that pre-labeled AMPARs underwent
degradation rapidly. These data suggest that patient anti-AMPAR antibodies increase the net
AMPAR internalization rate, and this loss of surface AMPARs is accompanied by transient
accumulation of internalized AMPARs.
Previous studies suggest internalized AMPARs are targeted to the early endosome, then
either recycled back to the surface, or transferred to late endosome and lysosome for
degradation.

17

In order to examine the compartmentalization of AMPAR clusters internalized by

patient antibodies, neurons were treated for 4 hours, a time point when internalized AMPARs
were ample, then stained for intracellular patient antibodies as well as early endosome (EEA1),
late endosome/lysosome (Lamp1), or recycling endosome (transferrin receptor, TrfR) markers
(Fig 3E, green indicates intracellular AMPARs labeled by patient antibodies, red indicates cell
compartment marker). A small percentage of intracellular patient antibody-bound AMPARs were
colocalized with the early endosome marker EEA1 or recycling endosome marker TrfR in
dendrites and cell bodies (Fig 3E, F). In contrast, in the cell body, 42±5% of these intracellular
AMPAR clusters were colocalized with the lysosome marker Lamp1. A similar colocalization of
intracellular AMPAR clusters with Lamp1 was observed in cells treated with control CSF (data not
shown).
These results suggest that patient antibodies increase the net internalization rate of
surface AMPARs and that internalized AMPARs are degraded in lysosomes.
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Commercial anti-AMPAR antibodies do not result in receptor internalization
We next examined whether commercially available anti-AMPAR antibodies have similar
effects on synaptic AMPAR clusters. After 1 day of treatment with a commercial anti-GluA1
antibody or anti-GluA2 antibody, the synaptic localization of AMPAR clusters was unchanged
across a wide range of antibody concentrations (Fig 4B). When the GluA1 antibody concentration
was high (dilution 1:20, 1:50), AMPAR cluster staining increased, most likely due to an increased
association of commercial antibodies with surface receptors in the absence of increased
internalization (Fig 4C; treatment with GluA1 at 1:50 dilution does not increase AMPAR
internalization). Interestingly, when a secondary antibody was included to cross-link the primary
antibody in neurons treated with anti-GluA2 antibodies, a significant decrease of synaptic AMPAR
cluster density was observed (Fig 4A, 4B).
To further confirm that treatment with commercial GluA2 antibodies plus secondary
increased net internalization of AMPARs while decreasing synaptic AMPARs, as observed with
patient antibodies, we examined the amount of internalized AMPARs. Neurons pre-labeled with
GluA1 antibodies were treated with commercial GluA1 antibodies, GluA2 antibodies with or
without secondary antibody or with patient CSF (Fig 4C). The patient CSF treated neurons had
the highest density of internalized AMPAR clusters, but commercial GluA2 plus secondary treated
neurons also had a significantly higher density of internalized AMPARs compared to baseline
levels. Neurons treated with commercial GluA1 or GluA2 antibodies alone did not show increased
accumulation of internalized AMPARs over 4 hours. These results suggest that some
commercially available primary-plus-secondary antibody complexes have a similar but less potent
effect on internalization of surface AMPARs as patient antibodies, while commercial anti-GluA
antibodies alone do not alter surface receptor localization.

Patient antibodies decrease AMPAR- but not NMDAR-mediated synaptic transmission
To determine whether patient antibodies reduce AMPAR-mediated synaptic transmission,
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AMPAR-mediated miniature excitatory postsynaptic currents (mEPSCs) were measured using
whole cell voltage clamp recordings from neurons treated with patient (anti-GluA1 or anti-GluA2)
or control CSF for 24 hours. Recordings were carried out in the presence of TTX, picrotoxin and
APV to block action potentials, GABAAR-mediated inhibitory currents and NMDAR-mediated
currents, respectively.
In neurons treated with control CSF, frequent AMPAR-mediated mEPSCs were observed
(Fig 5A, C, D). In contrast, the AMPAR-mediated mEPSCs in neurons treated with anti-GluA2
patient CSF were significantly smaller and less frequent. Thus, the anti-GluA2 patient antibodies
caused a significant decrease in mEPSC amplitude and frequency compared to controls, and this
was consistent with another recent report.

22

This decrease was also evident by 4 hours after

treatment (Fig 5C, D), consistent with immunostaining data demonstrating significant antibodymediated receptor internalization at this time point. Similar results were observed for anti-GluA1
patient antibody treated neurons. These results suggest that patient anti-GluA1 and anti-GluA2
antibodies decrease the amplitude and frequency of AMPAR-mediated mEPSCs in hippocampal
neurons.	
  	
  
To determine whether the effect of patient antibodies on synaptic currents is specific to
AMPARs, NMDAR-mediated currents were also measured. To measure these independently of
AMPAR-mediated mEPSCs, recordings were carried out in presence of TTX, picrotoxin, CNQX
(an AMPAR blocker), and glycine to reveal all functional NMDARs.

23

The amplitude, frequency

and decay time of NMDAR-mediated currents, which can be blocked by APV (Fig 5B, bottom
trace), were not significantly different in neurons treated with control or patient CSF (Fig 5B, E, F,
G). This result suggests that the patient antibodies specifically eliminate AMPAR function. Since
excitatory synapse density along dendrites assayed by immunostaining (Fig 2) was not altered,
the proportion of silent synapses without AMPARs was increased. In addition, the observation
that the frequency of NMDAR-mediated currents was not affected also suggests that
glutamatergic presynaptic release probability is unlikely to be altered by patient antibodies.
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These results show that patient antibodies specifically decrease synaptic AMPARmediated currents and not NMDAR-mediated currents, consistent with the specific loss of
surface, synaptically localized AMPAR clusters. The functional effect of antibody-mediated
AMPAR internalization is a weakening of glutamatergic synaptic transmission.

Compensatory decrease in inhibition in neurons treated with patient antibodies
Previous studies showed that chronic pharmacological blockade of AMPAR-mediated
transmission led to a homeostatic decrease of inhibitory synapse strength such that neurons
maintain their firing rate.

24–28

In order to examine whether similar compensatory changes

occurred following the decrease in AMPAR-mediated transmission induced by patient antibodies,
miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of TTX, APV
and CNQX. Measurements were done 48 hours after patient CSF treatment, and the decrease of
synaptic AMPARs assayed by immunostaining were comparable to 24 hours treatment. The
frequency of mIPSCs decreased significantly (Fig 6A-C) while the amplitude was comparable
between control and patient antibody treated conditions. To examine the effects of patient
antibodies on inhibitory synapses, neurons were immunostained with an inhibitory presynaptic
marker, vesicular GABA transporter (vGAT), and the postsynaptic GABAARβ2/3 (Fig 6D). Patient
CSF or CNQX treatment for 48 hours reduced vGAT staining intensity (Fig 6D, F), while the
density of inhibitory synapses defined by colocalization of vGAT and GABAAR clusters was
comparable among conditions. In order to confirm that the change of vGAT staining intensity was
not a direct result of patient antibodies but rather a reflection of decreased neuronal excitation,
coverslips were treated with KCl to depolarize neurons, increasing their activity, with or without
patient CSF. In conditions with KCl alone or KCl plus patient CSF, presynaptic vGAT cluster
intensity was increased significantly (Fig 6D, F), suggesting that changes in inhibitory tone were
determined by the level of neuronal excitation. Together these results suggest that neurons
homeostatically decrease inhibitory synaptic strength in response to the reduction in AMPARmediated synaptic transmission.
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Patient antibodies cause homeostatic increase of intrinsic excitability and altered action potential
firing
Previous work showed intrinsic neuronal properties are also affected by homeostatic
scaling.

29

Thus we examined the effect of patient anti-AMPAR antibodies on intrinsic neuronal

excitability in the presence of APV, CNQX, and PTX to block synaptic transmission. Neurons
rarely spontaneously fire action potentials under such conditions (Fig 7A, control 0 pA) since all
synaptic inputs are blocked, but fire upon current injection (Fig 7A). Neuronal excitability was
greatly increased after 48 hours of treatment with patient CSF. Neurons fired more action
potentials in response to the same amplitude of current injection (Fig 7A, B), and also fired action
potentials spontaneously (Fig 7B). After treatment with patient antibodies, input resistance was
increased (Fig 7C) while resting potential was not significantly altered (data not shown). These
results suggest that after treatment with patient anti-AMPAR antibodies, neurons are more
excitable, and tend to fire spontaneously without excitatory input.
In the absence of synaptic blockers, neurons treated with patient antibodies had a similar
average firing rate as control neurons (Fig 7E). The fidelity of firing rate was consistent with
previous observations that average firing frequency was usually maintained after blocking
excitatory synaptic transmission.

29–31

However, while average firing rate was unaffected by

patient antibodies, the pattern of firing was substantially altered. The inter-spike intervals of
neurons treated with patient CSF were significantly different from control neurons (Fig 7D, F).
Specifically, the percentage of spikes with extremely short inter-spike intervals (<10 ms) was
significantly increased in patient antibody treated neurons compared to controls (Fig 7G). These
results suggest that patient antibody-mediated reduction of surface AMPARs results in significant
changes in patterns of action potential firing in hippocampal pyramidal neurons.

83	
  

Discussion
We examined the effects of autoantibodies from anti-AMPAR encephalitis patients on
hippocampal neurons. Patient AMPAR antibodies cause a selective decrease in the surface
amount and synaptic localization of AMPARs, due to increased internalization of AMPARs.
Consistent with this, patient antibodies caused a decrease in AMPAR- but not NMDAR-mediated
excitatory postsynaptic currents. While the average action potential firing frequency was
unaffected, loss of surface AMPARs resulted in significant changes in the pattern of action
potential firing, likely a result of reduced inhibitory synaptic transmission and an increase in
intrinsic neuronal excitability. These results demonstrate patient antibodies induced synaptic and
neuronal changes that may contribute to the short-term memory loss and seizures observed in
patients with anti-AMPAR encephalitis.

Loss of surface AMPARs and deficits in hippocampal short-term memory
The phenotypes observed in mice lacking expression of individual AMPAR subunits are
not conjugate with symptoms observed in patients with anti-AMPAR encephalitis. Spatial learning
and memory are largely unaffected in GluA1 knockout mice.

11

GluA2 knockout mice show

reduced exploration, impaired motor coordination, abnormal spatial and non-spatial learning but
enhanced LTP.

14,32

These studies suggest that compensatory mechanisms, including expression

of other AMPAR subunits, may blunt the synaptic, circuit and behavioral effects of loss of a
particular receptor subunit. A recent study demonstrated that the surface pool of AMPARs is the
critical determinant of LTP, regardless of subunit types (Granger et al., 2013). This implies that if
the total surface AMPAR pool was decreased, memory problems would result. Our observation
that the total surface AMPAR pool is decreased in anti-AMPAR encephalitis regardless of the
antibody specificity, along with the loss of short-term memory in patients, provides strong support
for this hypothesis. Our data shows that patient antibodies against either GluA1 or GluA2 have
similar effects on the density of both GluA1 and GluA2 subunits, without obvious compensation
from the unaffected subunit. This is probably due to the fact that hippocampal AMPARs are
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mainly GluA1/GluA2 heteromers (Lu et al., 2009). Once the patient antibodies bind to either
subunit, they would initiate endocytosis of the entire AMPAR heteromer. Thus this form of
autoimmune encephalitis provides a unique human model, and informs development of potential
animal models, for understanding the role of AMPARs in learning and memory.
Another interesting aspect of anti-AMPAR encephalitis is the recovery process. Patient
short-term memory can recover after therapeutic intervention to reduce antibody titer. We
previously showed that after removal of patient antibodies, normal synaptic AMPAR cluster
3

density is restored within a few days in cultured neurons. Our current study showed that
inhibitory synaptic transmission and intrinsic neuronal properties were also altered after AMPARmediated synaptic transmission was reduced by treatment with patient antibodies. A number of
interesting questions remain about whether and how synapses and neuronal circuit properties
return to their original function during and after recovery. These questions could be explored in
longitudinal studies of animal models as well as human subjects before and after treatment to
reduce antibody titer.

Internalization of AMPAR triggered by patient antibodies
Antibodies trigger cross-linking and internalization of cell surface protein/antigen in single
cell pathogens,

33

blood cells,

NMDAR encephalitis.

16

34

muscle cells in myasthenia gravis,

35,36

and neurons in anti-

Pathogenic antibody induced internalization relies on specific epitopes on

antigens. Antibodies from several subgroups of patients with anti-NMDAR encephalitis recognize
a common epitope region based on the tertiary structure of amino acid residues that are remote
in primary sequence.

37

Antibodies from patients with myasthenia gravis also recognize a small

immunogenic region of nicotinic acetylcholine receptors (AChR).

38

Our results show that, in

contrast to patient antibodies, two commercially available antibodies against the amino-terminal
domain (ATD)

39

of AMPAR subunits do not induce internalization of surface AMPARs. One

hypothesis is that patient antibodies recognize a specific epitope region, which is not recognized
by commercial antibodies. Consistent with this hypothesis, anti-AMPAR encephalitis patient
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antibodies mainly recognize the bottom lobe of the ATD,
subunit of the NMDAR in anti-NMDAR encephalitis.

37

22

similar to antibodies against the NR1

In contrast, the peptide sequences used to

generate the commercial anti-AMPAR antibodies reside in the top lobe of the ATD for the antiGluA1 antibody (Calbiochem) and in both lobes for the anti-GluA2 antibody (Millipore). In our
experiments, the commercial anti-GluA1 did not increase AMPAR internalization, and previous
studies, which have used this antibody extensively for surface labeling of AMPARs, have not
reported effects on internalization. Interestingly, the addition of a secondary antibody (as a crosslinking agent) during anti-GluA2 treatment caused greater receptor internalization. These results
suggest that enhanced cross-linking of the commercial primary antibody caused increased
aggregation of the AMPAR-antibody complex resulting in receptor internalization. It is tempting to
speculate that the differential effects of the commercial antibodies may be a result of the location
of their epitopes on the AMPAR. Future studies will focus on examining whether specific amino
acid residues in bottom lobe of the ATD of ionotropic glutamate receptors may be critical for
autoimmunity. It also remains possible that different antibody isotypes

40

give rise to the difference

in AMPAR internalization, since the patient antibodies are mainly but not exclusively IgG,
commercial anti-GluA1 is polyclonal IgG, and commercial anti-GluA2 is monoclonal IgG2a. Our
experiments cannot rule out this possibility.
Due to the limited amount of high titer patient CSF and serum samples (2 high titer antiAMPAR patient samples sufficient for F(ab) fragment preparation, many fewer than anti-NMDAR
patient samples available for experiments), we were unable to directly assess the cross-linking
mediated by patients antibodies as in the previous work.

16

Preparing F(ab) fragments exhausts

large amount of patient samples due to protein loss in the digestion and purification steps. When
additional high titer patient samples are identified, patient antibody cross-linking of AMPARs can
be tested directly.
AMPARs are constantly cycling between the cell membrane and intracellular
compartments in normal neurons. Surface AMPARs are internalized, entering early endosomes
and sorting to recycling endosomes or late endosomes/lysosomes over a time course of minutes,
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depending on previous neuronal activity.
potentiation and depression,

42,43

17,41

These processes also contribute to long-term

which are thought to be critical in memory formation. Our results

showed that surface AMPAR loss was significant after 4 hours, consistent with a significant
decrease of AMPAR-mediated currents observed around the same time. One hour of patient CSF
treatment did not cause a significant decrease in surface AMPAR clusters but did cause a
significant increase of internalized AMPAR cluster density, probably due to the remaining large
pool of surface AMPARs (high noise compared to signal) but low background from internalized
AMPAR clusters (low noise compared to signal) for analysis. Our results do not suggest that the
anti-AMPAR patient antibodies slow normal AMPAR recycling which occurs on a timescale of
minutes. It is likely that individual AMPARs can be internalized minutes after
binding with patient antibodies. It is also likely that some of them recycle back to the surface since
about 10% colocalize with the recycling endosome marker TrfR. Thus the initial imbalance
between internalization and re-insertion is small. In addition, the binding of patient antibodies with
AMPARs does not saturate within minutes, but over hours, so the antibodies’ effects within the
first hour may not be maximal. Together, our results suggest that the balance of internalization
and reinsertion is disrupted in the presence of patient antibodies, culminating in the accumulation
of internalized AMPARs that becomes functionally significant after several hours. Our results
demonstrate that internalized AMPAR-antibody complexes are localized to early endosomes,
recycling endosomes and lysosomes, especially lysosomes in cell bodies; these are the cellular
compartments that normally contain constitutively internalized AMPARs.

17,41

The observations

reported here are made after pre-treatment of a population of surface AMPAR for over 2 hours,
and examining the distribution of these receptors after 4 hours, and thus represent a significantly
greater period of time than previous studies assaying activity-dependent AMPAR cycling.

17,41

data may reflect a steady-state distribution associated with the extended presence of patient
antibodies.
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Homeostatic plasticity associated with surface AMPAR loss caused by patient antibodies
It is a paradox that a decrease of AMPAR-mediated excitatory transmission could lead to
seizures in patients. Seizures usually result from an imbalance between excitation and inhibition,
either via an increase in excitation such as that caused by mutations in voltage-gated sodium
channels, or a decrease in inhibition such as that caused by GABAAR dysfunction.

44–48

An

exception involving a decrease of AMPAR-mediated synaptic transmission is the Stargazer
mutant mouse, which develops absence epilepsy due to reduced AMPAR-mediated synaptic
transmission in inhibitory thalamic reticular nucleus neurons, but not in excitatory relay neurons.

49

None of these previously reported mechanisms can fully explain the seizures in patients with antiAMPAR encephalitis. The work we report here suggests that the decrease of excitatory synaptic
transmission caused by patient antibodies results in a decrease in inhibitory synaptic
transmission and an increase in intrinsic excitability. These compensatory changes are consistent
with numerous observations that pyramidal neurons tend to homeostatically maintain firing rate in
response to chronic inactivity (Turrigiano et al., 1998; Burrone et al., 2002; Turrigiano, 2011).
Neurons treated with patient anti-AMPAR antibodies maintained a similar overall firing rate as the
control treated neurons, consistent with homeostatic compensation. However, at this new balance
point, a neuron might receive less synaptic input from other neurons and fire at a higher intrinsic
rate, generating epileptic activity. Patient anti-AMPAR antibodies selectively eliminate surface
and synaptic AMPARs, resulting in a homeostatic decrease in inhibitory synaptic transmission
and increased intrinsic excitability, which may trigger seizures in patients with this disorder.
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Figure 1: Patient anti-GluA1 or anti-GluA2 antibodies selectively decrease surface AMPAR
clusters.
(A) Hippocampal neurons immunostained with patient antibodies in CSF. Patient CSF was preincubated with control HEK cells, or HEK cells expressing GluA1/GluA2 for 45 minutes, 6 times to
deplete anti-GluA1/GluA2 antibodies. Control depleted patient CSF shows strong
immunoreactivity with neuronal surface antigens, GluA1/GluA2 HEK cell depleted patient CSF
show little immunoreactivity. Scale bar = 10 µm.
(B) Hippocampal neurons immunostained for GluA1- or GluA2-containing AMPAR clusters and
postsynaptic PSD-95. Synaptic AMPAR clusters appear yellow due to colocalization of green
GluA1 or GluA2/3 subunits and red PSD-95. Anti-GluA2 (middle panel) or anti-GluA1 (right panel)
patient CSF treatment for 24 hours reduced synaptic GluA2 as well as GluA1 cluster density
without affecting PSD-95 density (n=18-24 neurons from 3 independent experiments). Scale bar
= 5 µm.
(C) Quantification of synaptic GluA1 (left plot) or GluA2/3 (right plot) cluster density defined as
the colocalization between GluA1 or GluA2/3 and PSD-95 clusters per 20 µm dendrite length
from neurons treated with control, anti-GluA1 or anti-GluA2 patient CSF. The asterisk indicates
significant difference (compared with control, for synaptic GluA1 clusters, anti-GluA2 patient CSF
treatment = 60±7%, anti-GluA1 patient CSF treatment = 65±5%; one-way ANOVA, p=0.001; for
synaptic GluA2 clusters, GluA2 patient CSF treatment = 54±6%, GluA1 patient CSF
treatment=39±3%; one-way ANOVA, p<0.0001).	
  	
  
(D) Quantification of GluA1 (left plot) and GluA2/3 (right plot) cluster size (area of individual
cluster measured in thresholded image) from neurons treated with control, anti-GluA1 or antiGluA2 patient CSF. The asterisk indicates significant difference (compared to control, for GluA1
clusters, anti-GluA2 patient’s CSF treatment = 71±4%, anti-GluA1 patient CSF treatment =
78±5%; one-way ANOVA, p<0.0001; for synaptic GluA2 clusters, GluA2 patient CSF treatment =
79±4%, GluA1 patient CSF treatment = 84±7%; one-way ANOVA, p=0.01).
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(E) Quantification of GluA1 (left plot) and GluA2/3 (right plot) cluster intensity (average pixel
intensity of individual cluster) from neurons treated with control, anti-GluA1 or anti-GluA2 patient
CSF. The asterisk indicates significant difference (compared to control GluA1 clusters, anti-GluA1
patient CSF treatment = 84±5%; one-way ANOVA, p=0.03).
(F) Western blot analyses of surface biotinylated (upper) and intracellular (bottom) AMPAR
protein. Patient antibody treatment for 1 day reduces surface and total AMPAR subunits, but not
intracellular AMPARs. Surface GABAAR and intracellular MAP2 were used as loading controls for
surface and intracellular fractions, respectively (n=3 independent experiments).
(G and H) Quantification of band intensity of surface and intracellular AMPAR protein after
treatment with serum from anti-GluA1 or anti-GluA2 patients, showing a decrease in surface
GluA1 and GluA2/3 protein in both patient antibody treated neurons compared to control serumtreated neurons. The asterisk indicates significant difference (surface GluA1 band intensity,
control = 1±0.1, anti-GluA2 treated = 0.2±0.05, anti-GluA1 treated = 0.1±0.06; one-way ANOVA,
followed by Dunn's Multiple Comparison Test, p<0.0001; surface GluA2 band intensity, control =
0.9±0.1, anti-GluA2 treated = 0.4±0.01, anti-GluA1 treated = 0.5±0.08; one-way ANOVA, p<0.05);
and no	
  significant difference in intracellular GluA1 or GluA2/3 protein (one-way ANOVA, followed
by Dunn's Multiple Comparison Test, p>0.1).
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Figure 2: Patient anti-GluA1 or anti-GluA2 antibodies do not alter other synaptic proteins.
(A) Hippocampal neurons immunostained for the presynaptic marker vGlut or the postsynaptic
markers PSD-95, GluN1 or Stargazin. Anti-GluA2 patient CSF treatment for 24 hours does not
reduce vGlut, PSD-95, GluN1 and Stargazin cluster density (n=12-36 neurons from 2-3
independent experiments). Scale bar = 10 µm.
(B) Western blot analyses of surface biotinylated NMDAR, GABAB1R, and Stargazin protein (n=36 experiments).
(C) Quantification excitatory synapse density defined as the colocalization between postsynaptic
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PSD-95 and presynaptic vGlut density per 20 µm dendrite length from neurons treated with
control or patient CSF (control = 16±1, patient = 13±2; Mann-Whitney U test, p=0.1).
(D) Quantification of PSD-95 cluster density (control = 17±1, patient = 15±1; Mann-Whitney U
test, p=0.16), vGlut cluster density (control = 10±1, patient = 9±1; Mann-Whitney U test, p=0.16),
GluN1 cluster density (control = 17±1, patient = 16±1; Mann-Whitney U test, p=0.57),
Stargazin cluster density (control = 18±1, patient = 20±1.8; Mann-Whitney U test, p=0.33) per 20
µm dendrite length from neurons treated with control or patient CSF.
(E) Quantification of surface NMDAR, GABAB1R, and Stargazin protein after treatment with serum
from anti-GluA1 or anti-GluA2 patients, showing no significant changes in these surface proteins
(one-way ANOVA, p>0.1 for all tests).	
  	
  
(F) Quantification of the density of dissociated hippocampal cells in vitro after 1 day treatment
with control or patient CSF (untreated = 21±2, control treated = 20±2, patient treated = 20±2,
2

neurons per 750 µm , n=12 fields from 2 independent experiments; Kruskal-Wallis test, p=0.9).
(G) Quantification of the percent of TUNEL positive neurons in vitro (apoptotic cells). These
measures were not significantly different among untreated, control or patient CSF treatment
(untreated =0.0049±0.0049, control treated = 0.0135±0.0094, patient treated = 0.0052± 0.0052,
2

2

neurons per 750 µm , n=12 fields (750 µm ), 2 independent experiments; Kruskal-Wallis test,
p=0.7).
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Figure 3: Patient antibodies increase the internalization of AMPAR clusters.	
  	
  
Hippocampal neurons labeled live for surface AMPARs using commercial anti-GluA1 (comGluA1) for 1 hour, then treated with control or patient CSF for 1, 4 or 24 hours,
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followed by immunostaining for the remaining surface com-GluA1 in live neurons. In experiments
examining internalized com-GluA1, before fixation, neurons were pre-treated with an excess of
unconjugated secondary antibodies, then fixed, permeabilized and immunostained for internal
com-GluA1 (n=23 neurons from 3 separate experiments).
(A) Top and middle panels: Representative dendrites from neurons treated with control or patient
CSF respectively for 1, 4 or 24 hours and stained for surface com-GluA1. Patient CSF treatment
caused a greater decrease in surface GluA1 over a 24 hour time period than control. Bottom
image: dendrites pre-blocked with excessive non-fluorescent secondary antibodies and then
stained with fluorescent secondary antibody against com-GluA1, showing complete elimination of
surface staining signal. Scale bar = 10 µm.	
  	
  
(B) Representative dendrites from neurons treated with control (top) or patient CSF (bottom) for
1, 4 or 24 hours and stained for intracellular com-GluA1. Patient CSF treatment increased
intracellular com-GluA1 at 1 and 4 hours compared to controls. Scale bar = 10 µm.
(C) Quantification of surface com-GluA1 clusters from neurons treated with patient CSF for 1
hour compared with control neurons (per 20 µm dendrite length, control treated 1 hour = 20±1, 4
hours = 20±1, 24 hours = 12±1; patient CSF treated 1 hour = 20±1, 4 hour = 14±2, 24 hour = 2±1;
Mann-Whitney test, 1 hour p=0.3, 4 hour p=0.04, 24 hour p=0.002). The asterisk indicates
significant difference.
(D) Quantification of the density of intracellular com-GluA1 clusters from neurons treated with
control or patient CSF. The asterisk indicates significant difference (control treated 1 hour = 7±1,
4 hours = 5±0.4; 24 hours = 3±0.3; patient CSF treated 1 hour = 11±1, 4 hour = 14±2, 24 hour =
4±0.2; Mann-Whitney test, 1 hour p=0.03, 4 hour p=0.003, 24 hour p=0.007).
(E) Hippocampal neurons were treated with patient CSF for 4 hours, then surface patient
antibodies were pre-treated by non-fluorescent secondary, and then stained for intracellular
patient antibodies (green) and the following cell compartment markers (red): EEA for early
endosome, Lamp1 for lysosome or TrfR for recycling endosome. The upper panels show
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representative images of dendrites, the bottom panels show images of cell bodies (n=6-7 neurons
for each condition). Scale bar = 10 µm.	
  	
  
(F) Quantification of the percentage of internalized patient antibody clusters colocalized with each
cell organelle marker in dendrites (EEA = 7±1%, Lamp1 = 8±2%, TrfR = 13±2%).
(G) Quantification of percentage of internalized patient antibody clusters colocalized with each
cell organelle marker in cell bodies (EEA = 5±1%, Lamp1 = 42±5%, TrfR = 9±3%).	
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Figure 4: Commercial antibodies do not have the same effects as patient antibodies.
(A) Neurons were treated with PBS, commercial anti-GluA2 or anti-GluA1 antibodies directed
against extracellular epitopes, with and without secondary antibodies to crosslink the primary
antibodies, or secondary antibodies alone for 24 hours. Neurons were immunostained with an
anti-GluA1 antibody against an intracellular epitope (if treated with anti-GluA2 antibody) or directly
with fluorescent secondary (if treated with anti-GluA1) and for the presynaptic marker synapsin.
Commercial anti-GluA2 antibodies plus secondary antibody treatment for 24 hours decrease
synaptic GluA1 cluster density (the colocalized yellow puncta are green labeled GluA1 clusters
colocalized with red synapsin clusters, indicating synaptic GluA1; n=6-13 neurons from three
experiments.) Scale bar = 10 µm.
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(B) Quantification of the percentage of synaptic AMPAR cluster density per 20 µm dendrite length
from neurons treated with commercial GluA1 antibody or commercial GluA2 antibody compared
to neurons treated with PBS (compare to PBS control, GluA1 1:20 = 225±11%, GluA1 1:50 =
238±26%, GluA1 1:100 = 112±12%, GluA1 1:500 = 138±15%, GluA2 1:100 = 78±5%, GluA2
1:500 = 80±6%, GluA2 1:100 plus secondary = 61±5%, GluA2 1:500 plus secondary 1:500 =
44±3%, secondary only 1:500 = 91±13%. One-way ANOVA followed by Dunn’s multiple
comparison test, p<0.0001, asterisk indicates significant decrease, pound indicates significant
increase).	
  	
  
(C) Quantification of internalization of GluA1 clusters pre-labeled with a commercial antibody per
20 µm dendrite from neurons also treated with a commercial GluA1 antibody, a commercial
GluA2 antibody or patient antibodies (n=11-13 neurons from 3 experiments, 0 hours = 1±0.3,
GluA1 1:100= 2±0.4, GluA1 1:50 = 2±0.5, GluA2 1:500 4 hours = 4±0.4, GluA2 plus secondary
1:500 = 9±0.8, patient CSF = 17±1; Kruskal-Wallis test, p<0.0001, asterisk indicates significant
difference).
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Figure 5: Patient antibodies decrease AMPAR- but not NMDAR-mediated synaptic
transmission.	
  
(A) mEPSCs recorded in physiological saline with TTX, picrotoxin, and APV to isolate synaptic
AMPAR-mediated currents (upper trace; n=9 neurons treated with control CSF, 4-7 neurons
treated with patient CSF for 1, 4 or 24 hours). Left: Under the same recording conditions,
treatment of hippocampal neurons with patient CSF (bottom traces) for 1 day dramatically
reduces synaptic AMPAR-mediated currents. Right: Representative average mEPSCs from
neurons treated for 1 day with control CSF (left) or patient CSF (right). Neurons treated with
patient CSF have smaller AMPAR-mediated synaptic current than neurons treated with control
CSF.
(B) mEPSCs recorded in physiological saline with TTX, picrotoxin and CNQX, to isolate synaptic
NMDAR-mediated currents. Left: Neurons treated with control (upper trace) and patient CSF
(bottom traces) for 1 day have comparable synaptic NMDAR-mediated currents. Right:
Representative average mEPSCs from neurons treated for 1 day with control CSF (left) or patient
CSF (right), showing comparable synaptic NMDAR-mediated currents (n=10 neurons treated with
control CSF, 9 neurons treated with patient CSF.
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(C) Effect of patient antibodies on AMPAR-mediated synaptic current amplitude (in pA, control =
15±1, patient CSF treated 1 hour = 12±2, patient CSF treated 4 hours = 10±1, patient CSF
treated 24 hours = 10±1; asterisk indicates significant difference, one-way ANOVA, p=0.01).	
  	
  
(D) Effect of patient antibodies on AMPAR-mediated synaptic current frequency (in Hz, control =
8±1, patient CSF treated 1 hour = 5±2, patient CSF treated 4 hours = 2±0.4, patient CSF treated
24 hours = 2±0.8; asterisk indicates significant difference, one-way ANOVA, p=0.0017).
(E) Effect of patient antibodies on NMDAR-mediated synaptic current amplitudes (in pA, control =
16±1, patient CSF treated = 18±2; Student’s t-test, p=0.2).	
  	
  
(F) Effect of patient antibodies on NMDAR-mediated synaptic current frequency (in Hz, control =
0.7±0.1, patient CSF treated = 1±0.3; Student’s t-test, p=0.44).
(G) Effect of patient antibodies on NMDAR-mediated synaptic currents decay time (in ms, control
= 66±9, patient CSF treated = 88±8; Student’s t-test, p=0.09).	
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Figure 6: Homeostatic decrease of GABAAR-mediated synaptic transmission.
(A) mIPSCs were recorded in physiological saline with TTX, CNQX and APV to isolate synaptic
GABAAR-mediated currents. Hippocampal neurons treated with patient CSF (bottom left trace) for
1 day have fewer mIPSCs compared to control (upper left trace). The average amplitude of
GABAAR-mediated mIPSCs in neurons treated with patient CSF (bottom right trace) was similar
from control (bottom left trace; n=8 control CSF treated neurons, 6 patient CSF treated neurons).
(B) Effect of patient antibodies on GABAAR-mediated mIPSC frequency (in Hz, control = 1.6±0.5,
patient CSF treated = 0.4±0.2; asterisk indicates significant difference, Student’s t-test, p=0.03).
(C) Effect of patient antibodies on GABAAR-mediated mIPSC amplitudes (in pA, control = 37±2,
patient CSF treated = 35±3; Student’s t-test, p=0.7).
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(D) Hippocampal neurons immunostained for the inhibitory presynaptic marker vGAT (red) and
the postsynaptic marker GABAAR (green). Inhibitory synapses are defined as the colocalization
between vGAT and GABAAR staining. Patient CSF or CNQX treatment for 24 hours reduces
vGAT staining intensity, while patient CSF plus KCl (25 mM) increases vGAT intensity, compared
to neurons treated with control CSF (n=15-24 neurons from 3 independent experiments). Scale
bar = 10 µm.
(E) Quantification of inhibitory synapse density. Numbers of immunofluorescence labeled puncta
per 20 µm dendrite were normalized to controls for each trial. Neurons were treated with control
CSF,	
  patient CSF, CNQX, patient CSF plus KCl (25 mM) or KCl (25 mM). The density of
inhibitory synapses was comparable among conditions (Mann-Whitney U test, p=0.5).
(F) Cumulative distribution of vGAT intensity on neurons treated with control CSF (black solid
line), patient CSF (red solid line), CNQX (green solid line), patient CSF plus KCl (red dotted line)
or KCl (black dotted line). Patient CSF or CNQX treated neurons have decreased vGAT staining
intensity compare to the control (Kolmogorov–Smirnov test, p<0.0001), while KCl alone or KCl
plus patient CSF treated neurons have increased vGAT staining (Kolmogorov–Smirnov test,
p<0.0001).	
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Figure 7: Homeostatic increase of neuronal excitability and patient antibody effects on
spontaneous firing.
(A) Representative traces of action potential firing during current injection (upper traces, 0 pA, 40
pA, 100 pA, 200 pA) in control treated neurons (middle traces), and patient CSF treated neurons
(bottom traces). The recording was done in the presence of APV, CNQX and PTX to block
synaptic transmission (n=7 control neurons, 6 patient CSF treated neurons).
(B) Quantification of action potential firing versus current injection, showing significant increase
of neuronal excitability in patient CSF treated neurons (Mann-Whitney U test, p<0.05 for 0, 40,
60, 80,100, 120, 140, 180 and 200 pA).
(C) Average input resistance was higher in patient CSF treated neurons than in controls (in MΩ,
control = 294±29, patient CSF treated = 448±51; asterisk indicates significant difference,
Student’s t-test, p=0.04).
(D) Representative traces of spontaneous action potential firing in control (upper trace) or patient
CSF treated neurons (bottom trace) without synaptic transmission blockers. The boxed segments
are	
  shown at slower time scale on the right (n=5 control neurons, 6 patient CSF treated neurons).
(E) Average action potential firing frequency was not significantly different in control or patient
CSF treated neurons (in Hz, control = 1.6±0.3, patient CSF treated = 1.7±0.5, Student’s t-test,
p=0.9).
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(F) Cumulative distribution of action potential inter-spike intervals of neurons treated with control
CSF (dotted line) or patient CSF (solid line). Asterisk indicates that these two distributions are
significantly different (Kolmogorov–Smirnov test, p<0.0001).
(G) Comparison of percentage of short interval spikes (with <10 ms intervals) in control treated or
patient CSF treated neurons (in %, control treated = 1.3±0.7, patient treated = 11±5; asterisk
indicates significant difference, Student’s t-test, p=0.02).
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Table 1: Patient samples used in each experiment and specific antibodies in each sample
Figure Number

Experiment/treatment

1A

Hippocampal neuron
immunostaining with patient CSF

1B-E

Treatment with patient CSF and
immunostaining of synaptic
AMPAR clusters

09-276 (GluA1), 04-067
(GluA1), 02-066 (GluA2)

1F-H, 2B,E

Treatment with patient serum and
Western analysis

04-067 serum (GluA1), 02066 serum (GluA2)

2A, C, D

Treatment with patient CSF and
immunostaining of other synaptic
markers

04-067 (GluA1), 02-066
(GluA2)

2F, G

Treatment with patient CSF and
cell death analysis

02-066 (GluA2)

3

Treatment with patient CSF and
internalization assay

02-066 (GluA2)

5

Treatment with patient CSF and
recording of AMPAR and
NMDAR-mediated miniature
currents

04-067 (GluA1), 02-066
(GluA2)

6

Treatment with patient CSF and
GABAAR-mediated currents

02-066 (GluA2)

7A-D

Treatment with patient CSF and
cell excitability

02-066 (GluA2)

7E-G

Treatment with patient CSF and
cell spontaneous firing

04-067 (GluA1)
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Patient CSF ID (Specific
antibodies
04-067 (GluA1), 02-066
(GluA2)
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Abstract
Objective: Antibodies from patients with anti-NMDAR encephalitis cause homeostatic
plasticity of inhibitory synapse density. In this study, we sought to determine if intrinsic excitability
was also altered, and possible mechanisms underlying the expression of this plasticity. In
addition, we establish and validate organotypic hippocampal slice cultures as a new model
system for cellular and circuit studies of autoimmune encephalitides.
Methods: Current-clamp recordings from dissociated hippocampal neurons were made to
measure antibody-induced changes in intrinsic excitability. Organotypic hippocampal slice
cultures were used to assay effects of patient antibodies on NMDAR clusters and currents, and
interneuron integrity.
Results: Patient antibody treatment increased neuronal excitability in dissociated
hippocampal neurons. Input resistance and threshold to firing remained unchanged, while the
resting membrane potential became depolarized. Action potential height, width, and
accommodation were unchanged, as were voltage-gated potassium currents. Treatment of
organotypic hippocampal slices with patient antibodies caused a decrease in NMDAR-mediated
field potentials, as well as NMDAR staining, protein levels and parvalbumin immunoreactivity,
without changes in the pan-interneuron marker GAD65/67.
Interpretation: These results demonstrate that anti-NMDAR antibodies can induce
homeostatic plasticity of intrinsic excitability, and that different membrane properties may underlie
this phenomenon following anti-NMDAR and anti-AMPAR antibody treatment. Hippocampal slice
cultures can be used as a more intact system to investigate synaptic and circuit effects of
antibody treatment, and resultant homeostatic changes in these circuits.
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Introduction
Homeostatic plasticity is an important and widespread mechanisms for stabilizing
neuronal activity in the face of fluctuations due to development, disease, or Hebbian synaptic
1

plasticity. In contrast to other forms of plasticity, such as long-term potentiation and depression,
which operate on a time scale of minutes to hours, homeostatic plasticity is thought to emerge
over longer time frames, from many hours to days. Pharmacological manipulations that increase
or decrease activity levels can trigger distinct forms of homeostatic plasticity, expressed at the
2

synapse or through intrinsic membrane properties. Alone or in combination, these modifications
tend to allow neurons to maintain a set-point level of activity.
Paradoxically, seizures are a major symptom of both anti-NMDAR and anti-AMPAR
encephalitis.

3,4

The seemingly contradictory nature of two diseases marked by a loss of excitatory

glutamate receptors leading to the development of epileptic seizures can be reconciled within the
context of homeostatic plasticity. Although commonly thought of as an adaptive or stabilizing
force, there are instances of homeostatic plasticity inadvertently creating an imbalance in
excitation versus inhibition,

5-7

that could become pathological.

Previous work has shown that neurons treated with patient anti-AMPAR antibodies
compensate for reduced excitatory drive through glutamatergic synapses by adjusting inhibitory
8

synapse strength and intrinsic excitability, but at the expense of firing pattern fidelity. Similarly,
anti-NMDAR antibodies cause a homeostatic decrease in inhibitory synapse density onto
9

excitatory neurons, but their effect on neuronal excitability is unknown. Other models of NMDAR
hypofunction have reported plasticity of intrinsic excitability,

10

raising the possibility that patient

antibodies generate a similar response. A second possible mechanism that could underlie seizure
development in anti-NMDAR encephalitis is dysfunction in a subset of inhibitory neurons, the fastspiking parvalbumin-positive (PV+) interneurons, an occurrence known to take place in several
pharmacological and genetic models of NMDAR hypofunction.

10-14

Here we investigated these two possible causes of altered excitatory-inhibitory balance in
response to anti-NMDAR antibodies. We report that patient antibodies increase cultured
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hippocampal neuron excitability, possibly through a depolarization of the resting membrane
potential. In addition, we established an organotypic hippocampal slice culture system and
verified that patient antibody treatment decreased NMDAR protein levels and NMDAR-mediated
field potentials. Finally, we used the hippocampal slices to assay changes in parvalbumin
immunoreactivity and found that patient antibodies cause a decrease the intensity of parvalbumin
staining but not in the number of parvalbumin-positive cells, without changes in the paninterneuron marker GAD65/67. Together, these data further our understanding of homeostatic
mechanisms in this disease, and set the stage for future studies in in vivo models.
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Materials and Methods
Cell culture and treatment
Hippocampal neurons were prepared and maintained from embryonic day 18 rat pups as
previously described.

15

Neurons were treated on in vitro day 14-16 (DIV14-16) with cerebrospinal

fluid (CSF) from patients or controls at a dilution of 1:20.

Organotypic slice culture and treatment
Hippocampal slice cultures were prepared from rat pups P5-7 as previously described.

16

Briefly,

pups were anesthetized and hippocampi dissected in ice-cold, oxygenated ACSF containing the
following in mM: 85 NaCl, 2.5 KCl, 1.25 NaH2PO4, 75 sucrose, 25 glucose, 0.5 ascorbic acid, 4
MgSO4, 25 NaHCO3, 0.5 CaCl2. 300 µm-thick sections were cut on a McIlwain tissue chopper
and plated onto Millipore cell culture inserts in slice culture media (8.4 g/L MEM Eagle medium,
20% horse serum, 1 L-glutamine, 1 CaCl2, 2 MgSO4, 1 mg/L insulin, 0.00125% ascorbic acid, 13
glucose, 5.2 NaHCO3, 30 HEPES). Slices were maintained in a humidified incubator at 37°C with
5% CO2.

Immunostaining
Slice cultures were treated for 72 hours and incubated with the following primary antibodies: to
label NMDARs, anti-GluN1 (Millipore; AB9864R, 1:100); inhibitory neurons, anti–glutamic acid
decarboxylase 6 (GAD6; Developmental Studies Hybridoma Bank, Iowa City, IA; 1:20);
parvalbumin-positive neurons, anti-parvalbumin (Sigma; P3088, 1:100). The secondary
antibodies (Invitrogen) were raised in goat against rabbit, mouse, or human immunoglobulin G
(IgG) and conjugated to various Alexa Fluor dyes. Slices were mounted and imaged on a
confocal microscope (Leica, Wetzlar, Germany; TCS SP5) and analyzed using interactive
software (custom-written ImageJ macros).

15
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Western blot
Slice cultures were washed with PBS and lysed in RIPA buffer (150mM NaCl, 1mM EDTA,
100mM Tris-HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH=7.4), supplemented
with 1:500 protease inhibitor mixture III (Calbiochem) at 4°C for 1 h. Lysates were sheared by
passage through a 22-gauge syringe and cleared of debris by centrifugation at 12,4000g for 20
minutes. Protein samples were separated on 4-15% SDS-PAGE gel and transferred to
nitrocellulose membranes. Blots were probed with antibodies against GluN1 (Millipore, 1:1000)
and MAP2 (Abcam, 1:1000).

Electrophysiology
Whole-cell current-clamp recordings were performed at room temperature using a Multiclamp
700B amplifier and pClamp 10 data acquisition software. Neurons were incubated in extracellular
physiology solution (in mM): 140 NaCl, 3 KCl, 0.6 MgCl2, 2.5 CaCl2, 10 HEPES, 10 glucose.
Picrotoxin (10 µM), APV (50 µM) and CNQX (10 µM) were added to block synaptic currents.
Borosilicate glass microelectrodes (resistance 4-6 M) filled with intracellular solution (in mM): 140
KCl, 2 MgCl2, 11 EGTA, 10 HEPES, 7 glucose, pH=7.3. Traces were amplified, sampled at 20
kHz, then digitally low-pass filtered at 2.5 kHz and events were analyzed using Clampfit.
For field potential recordings, slice cultures were placed in a recording chamber and perfused
with warmed (30°C), oxygenated ACSF containing (in mM): 126 NaCl, 2.5 KCl, 1.25 Na2HPO4, 10
glucose, 26 NaHCO3, 2.5 CaCl2. Picrotoxin (10 µM) and CNQX (10 µM) were added to isolate
NMDAR-mediated potentials. A bipolar stimulating electrode was placed near the border of CA3CA1 in the Schaffer collaterals, and an ACSF-filled recording electrode (resistance 1-2MΩ) was
placed in the stratum radiatum in CA1. Evoked field potentials were amplified, sampled at 20 kHz,
then digitally low-pass filtered at 2.5 kHz and slopes were analyzed using Clampfit.

Statistical analysis
Data sets were analyzed using a Mann-Whitney U test or 2-way analysis of variance test.
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Results
Patient anti-NMDAR antibodies cause a homeostatic increase in intrinsic excitability
Patient antibodies abrogate NMDAR-mediated miniature excitatory postsynaptic currents
in hippocampal neurons in vitro,

15

and cause a resultant compensatory decrease in inhibitory
9

synapse density onto pyramidal neurons. To assess whether another common locus of
homeostatic plasticity, intrinsic excitability, was altered in response to patient cerebrospinal fluid
(CSF) treatment, hippocampal neuron cultures (DIV15-18) were treated for 24-48 hours. Wholecell current clamp recordings were used to measure action potential firing frequency in response
to depolarizing current injection in the presence of synaptic blockers.
Hippocampal neurons rarely fire spontaneously under such conditions, but current
injection will elicit one or more action potentials (Fig 1A). Patient CSF treatment increases the
number of action potentials fired in response to injection of a given amount of current, and also
causes neurons to fire more spontaneous action potentials even in the absence of stimulation
(Fig 1A, B).
This phenomenon also occurs following treatment with anti-AMPAR antibodies.

8

Interestingly, our data suggests that different mechanisms may underlie the increased excitability
in these two cases. Treatment with anti-NMDAR encephalitis patient CSF significantly
depolarizes the resting membrane potential (Fig 1C) with no change in either threshold to firing or
input resistance (Fig 1D). In contrast, hippocampal neurons treated with CSF from patients with
anti-AMPAR encephalitis have no change in resting membrane potential or threshold to action
8

potential firing, but input resistance is increased ( and Figure 1D).
These results suggest that exposure to anti-NMDAR and anti-AMPAR antibodies leads to
an increase in intrinsic neuronal excitability, but that these different scenarios may engage
separate mechanisms to achieve this compensation.
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Patient antibody treatment does not change spike frequency adaptation or action potential shape
To gain further insight into the ionic mechanisms underlying the increased excitability of
hippocampal neurons treated with anti-NMDAR antibodies, we analyzed certain well-defined
parameters of action potential firing. The first was spike frequency adaptation (SFA), the
reduction of firing frequency over time during current injection,
by multiple ionic currents.

18,19

17

a process that can be influenced

The ability of neurons to fire more action potentials in response to a

given amount of current could be due to attenuated SFA during the current step. SFA was
measured as the ratio of initial firing frequency to final firing frequency.

18

Both control and patient

treated neurons showed this adaptation (SFA>1), and the magnitude as a function of current
injection was not different between conditions (Fig 1E).
Next, we measured action potential width, height, and peak voltage, characteristics that
can also be modulated by multiple conductances. None were altered by patient antibody
treatment (Fig 1F-H). Last, we measured voltage-gated potassium currents, a large family known
to have varied effects on firing frequency and excitability. Neither current amplitude nor voltagedependence of activation was altered (Fig I, J).

Patient antibodies decrease NMDAR clusters and currents in organotypic hippocampal slice
cultures
The use of dissociated hippocampal neuron cultures facilitated a detailed mechanistic
description of antibody-mediated NMDAR and AMPAR hypofunction and the homeostatic
response of hippocampal neurons to the loss of glutamatergic synaptic transmission. To begin to
narrow the gap between a model of cultured neurons and disease, an organotypic hippocampal
slice culture system was established. Organotypic hippocampal slices are an ideal preparation for
our studies, because they largely retain the synaptic circuitry and developmental trajectory found
in vivo, are amenable to physiological and histological assays, and can be maintained for up to
three weeks in culture,

20

allowing for multi-day treatment with patient antibodies. Slices were
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prepared from P5-7 rat pups, and used for immunohistochemistry, Western blotting and
physiology between DIV7-14.
Following treatment with patient CSF, slices were stained with deposits of human
immunoglobulin (IgG) and the intensity of NMDAR immunoreactivity was significantly decreased
(Fig 2A,C). This result was verified with Western blotting (Fig 2B), and mirrors results in
dissociated hippocampal neurons.
Extracellular recordings were made to measure the effects of patient CSF on evoked
NMDAR currents. We focused on the Schaffer collateral pathway, where axon collaterals from
CA3 pyramidal neurons synapse onto the dendrites of CA1 pyramidal neurons and in which
dynamics of glutamatergic transmission have been well described. Schaffer collateral axons were
stimulated in CA3 and the resultant field excitatory postsynaptic potentials (fEPSP) were
measured in the stratum radiatum of CA1. CNQX (10 µM) and picrotoxin (10 µM) were added to
isolate the NMDAR component of the fEPSP. Patient CSF caused a decrease in the slope of the
NMDAR-mediated fEPSPs (Fig 2D), indicating a loss of postsynaptic NMDAR-mediated currents.
These data together show that, as in dissociated hippocampal neurons, patient antibody
treatment causes a loss of NMDAR clusters and currents in hippocampal slices.

Patient antibodies alter parvalbumin immunoreactivity
In hippocampal neuron cultures, NMDAR hypofunction due to treatment with patient CSF
results in a homeostatic decrease in inhibitory synapse density onto excitatory pyramidal
9

neurons. In several genetic and pharmacological models of NMDAR hypofunction, there are
abnormalities specifically in PV+ interneurons, including a decrease in mRNA and protein
expression of the calcium binding protein for which the cell type is named, parvalbumin.

10-14

As

these neurons target perisomatic regions and axon initial segments of pyramidal neurons, they
exert a powerful influence on neuronal firing and synchrony, and therefore information processing
in the brain.

21-23

To test if anti-NMDAR antibodies elicited similar alterations in parvalbumin
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expression, hippocampal slice cultures were treated with patient CSF and processed for
immunohistochemistry.
The number of PV+ interneurons was unchanged following treatment (Fig 2E); however,
the intensity of immunoreactivity per neuron was decreased (Fig 2F). There were no changes in
expression of GAD65/67 (Fig 2E, F). This is consistent with studies from other models,

14

and

suggests that like pharmacological models of NMDAR hypofunction, PV+ interneuron dysfunction
may be a pathologic mechanism in anti-NMDAR encephalitis.
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Discussion
We have described two effects of anti-AMPAR and anti-NMDAR antibody treatment that
could plausibly lead to the development of seizures in patients. The first is homeostatic plasticity
of intrinsic excitability, which augments action potential firing, and in the case of anti-AMPAR
encephalitis, changes the firing pattern. The second is a loss of parvalbumin immunoreactivity, in
response to anti-NMDAR antibodies, in a subset of hippocampal interneurons, indicative of
inhibitory neuron dysfunction. These changes, while probably engaged as neurons attempt to
compensate for the antibody-induced partial loss of excitatory synaptic transmission, may instead
lead to hyperexcitability and contribute to patient symptoms and disease progression.

Mechanisms of homeostatic plasticity
Action potential firing is the major output mode for neurons. As such, it is a variable and
tightly regulated code. Apart from diverse spatial and temporal combinations of synaptic input,
action potential firing can be shaped by the vast repertoire of ion channels embedded in the
neuronal membrane.

24

Homeostatic plasticity of intrinsic excitability could engage any number of

these conductances. In cortical neurons, activity blockade leads to an increase in excitability that
is mediated by a decrease in threshold to firing, an increase in voltage-gated sodium
25

conductance and a decrease in persistent outward potassium currents. These changes may be
downstream of BDNF.

26

In guinea pigs and rats, unilateral vestibular lesions produce a

compensatory increase in firing in neurons on the injured side through the concerted actions of
several conductances.

27,28

In invertebrate systems, isolation of neurons in culture initially

abrogates firing, but normal activity patterns recover within a few days, as a result of modulation
of several intrinsic conductances, including sodium, potassium, and calcium currents.

29

In the case of anti-NMDAR antibodies, the resting potential is depolarized compared with
control treatment. This could arise from changes in several potassium conductances, including
inward rectifiers (KIR),

30,31

+

2 pore domain K channels (K2P),

32

or M-currents (KCNQs).

33

In

contrast, anti-AMPAR antibodies increase the input resistance of the neuronal membrane,
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indicating a decreased density of one or more types of channels normally open at hyperpolarized
resting potentials.

34

The enhanced excitability of neurons following anti-NMDAR antibody exposure is
consistent with other models of NMDAR hypofunction. Ketamine, an NMDAR blocker, activates
the prefrontal cortex in humans and rats.

35,36

MK-801, a use-dependent NMDAR antagonist,

decreases the firing rate of interneurons and increases the rate of pyramidal neuron firing in the
hippocampus.

37

Chronic MK-801 decreases inhibitory post-synaptic potential (IPSP) amplitude in

CA1 hippocampal neurons.

14

Interestingly, infusion of CSF from anti-NMDAR encephalitis

patients raises concentrations of extracellular glutamate in hippocampus and cortex.

38

While

these findings are usually attributed to synaptic effects (i.e., loss of NMDAR function on inhibitory
interneurons causing disinhibition of excitatory neurons), our findings raise the possibility that
changes in intrinsic excitability may play an additional role.
The observed increase in excitability may help explain not only patient seizures, but also
other cognitive deficits. There is a high link between seizures and many neuropsychiatric
conditions.

39-41

Disturbances in the excitatory-inhibitory balance have been connected with both

autism and schizophrenia, and increasing the ratio of excitation to inhibition leads to behavioral
impairments in rodent models, including diminished social interactions and impaired fear
learning.

10,42-45

The input-output curves of individual neurons are more easily saturated, which

could cause problems with information processing and learning and memory.

42

These data

support the idea that altered excitatory-inhibitory balance in anti-glutamate receptor
encephalitides may be at the root of many seemingly diverse symptoms.

Parvalbumin-positive interneuron dysfunction
Another common finding among disparate models of impaired NMDAR hypofunction is
abnormal gene and protein expression in PV+ interneurons.

10-14

Axon terminals of this class of

fast-spiking inhibitory neuron target the axon initial segment and perisomatic regions of excitatory
neurons, exerting a powerful influence on pyramidal neuron firing and synchrony.
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21-23

PV+

neurons are instrumental for rhythmogenesis, especially for synchronizing gamma-frequency
oscillations, which have a crucial role in facilitating working memory and perceptual binding. In
fact, behavioral deficits in a model of excitation-inhibition imbalance can be rescued by exciting
PV+ interneurons.

42

The power of gamma-frequency oscillations is often disrupted in

schizophrenia, in human patients and animal models.

46

Consistently, the proper functioning of

PV+ interneurons has become a fruitful source of inquiry in the field of schizophrenia research.
Post-mortem studies of schizophrenia patients have revealed several consistent
findings.

47

Gamma-aminobutyric-acid (GABA) expression is reduced in PV+ interneurons, as is

expression of GAD65/67, a GABA synthesizing enzyme. The mRNA and protein levels of
parvalbumin are also diminished. One explanation for this finding again invokes homeostatic
2+

plasticity; as a calcium-binding protein, parvalbumin abrogates the Ca -based facilitation of
GABA release from presynaptic terminals. As inhibitory synapse density and the immunoreactivity
of vGAT+ terminals falls in response to loss of glutamatergic drive, levels of PV may decrease to
enhance GABA release.
Interestingly, NMDARs have a prominent role in proper PV+ interneuron functioning. PV+
interneurons have substantial NMDAR-driven synaptic responses,

48

and ablation of NMDARs on

this class of interneurons impairs firing in the gamma and theta frequencies, leading to deficits in
spatial recognition memory, working memory, and sociability.

49,50

Following administration of

many pharmacological NMDAR blockers, including ketamine and phencyclidine (PCP), and in a
genetic rodent model of NMDAR hypofunction, parvalbumin expression is diminished.

10-14

Consistently, treatment of organotypic hippocampal slices with anti-NMDAR antibodies decreases
parvalbumin expression. Together with other data, we have identified at least three potential
routes by which patient antibodies could perturb excitatory-inhibitory balance, leading to seizures
and cognitive deficits—reduced density of inhibitory presynaptic terminals, enhanced intrinsic
excitability, and a loss of parvalbumin expression.
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Establishment of organotypic hippocampal slice system
We described the development of a new model for future studies of patient antibody
effects. Organotypic hippocampal slices have several advantages over dissociated hippocampal
neurons. First, hippocampal architecture remains intact, allowing for an analysis of the structure
and function of the circuits therein after antibody treatment. Second, the older age of the animals
used to generate slices means gene expression of certain interneuron classes has turned on,
such as parvalbumin. Finally, phenomena such as homeostatic plasticity, which may be
expressed differently in culture versus an intact slice, can be studied in a more physiologically
relevant context.

16,20

Along with a recently developed animal model of anti-NMDAR encephalitis,

hippocampal slice cultures will allow the gap between synaptic mechanisms of dysfunction and
human disease to begin to narrow.
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Figure 1: Patients antibodies cause a homeostatic increase in neuronal excitability
(A) Representative traces of action potential firing during current injection (upper traces, 0 pA, 40
pA, 100 pA, 200 pA) in control treated neurons (middle traces), and patient CSF treated neurons
(bottom traces; (n=6 control neurons, 6 patient CSF treated neurons).
(B) Quantification of action potential firing versus current injection, showing significant increase
of neuronal excitability in patient CSF treated neurons (Mann-Whitney test, p<0.05 for 170, 270,
and 290 pA).
(C) Average input resistance in control (370.7±61.2 MΩ) and patient (321.0±84.06) treated
neurons was not significantly different (Mann-Whitney test, p>0.05).
(D) Quantification of average resting membrane potential for control versus NMDAR CSF treated
(top left, -66.35±2.16 and -58.77±1.77) and control versus AMPAR CSF treated neurons (top
right, -58.73±3.27 and -52.15±0.93), and average threshold for firing for control versus NMDAR
CSF treated (bottom left, -31.56±3.86 and -36.44±1.36) and control versus AMPAR CSF treated
neurons (bottom right, -35.00±1.13 and -34.83±0.90). Only the difference in resting potential for
NMDAR CSF treated neurons was significantly different (Mann-Whitney test, p<0.05).
(E) Quantification of spike frequency adaptation (SFA) ratio versus current injection, showing no
change between control and patient CSF (Mann-Whitney test, p>0.05).
(F) Quantification of action potential height versus current injection, showing no change between
control and patient CSF (Mann-Whitney test, p>0.05).
(G) Quantification of action potential width versus current injection, showing no change between
control and patient CSF (Mann-Whitney test, p>0.05).
(H) Quantification of action potential amplitude versus current injection, showing no change
between control and patient CSF (Mann-Whitney test, p>0.05).
(I) Current-voltage (I-V) curves for voltage-gated potassium currents; current amplitudes for a
given holding voltage are unchanged by patient antibody treatment.
(J) Voltage-dependence of potassium channel activation is unchanged by patient antibody
treatment.
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Figure 2: Patient antibodies decrease NMDAR clusters and currents and parvalbumin
immunoreactivity in organotypic hippocampal slice cultures
(A) Hippocampal slice cultures were immunostained for total GluN1 and human IgG following
treatment for 72 hours with control or patient CSF and imaged with confocal microscopy. Scale
bar = 50 µm
(B) Hippocampal slice cultures were processed for Western blotting following treatment for 72
hours with control or patient CSF. Blots were probed for GluN1, and MAP2 was used as a loading
control. Patient CSF treatment causes a decrease in GluN1 protein levels.
(C) Quantification of GluN1 and human IgG staining intensity. Patient antibody treatment caused
a significant decrease in GluN1 immunoreactivity (78.50±6.54% of control), and a significant
increase in human IgG staining (218.8±25.79% of control; n=22-34 slices from 4 independent
experiments). Asterisk indicates significance; Mann-Whitney test, p<0.05.
(D) Hippocampal slice cultures were treated for 72 hours with control or patient CSF, then
extracellular recordings were made from the stratum radiatum of CA1. The slope of the NMDARmediated portion of the field excitatory postsynaptic potential (fEPSP) was significantly decreased
following patient antibody exposure (control, 0.40±0.06; patient 0.20±0.07; n=4). Asterisk
indicates significance; Mann-Whitney test, p<0.05.
(E) Hippocampal slice cultures were immunostained for parvalbumin and a pan-inhibitory marker,
GAD65/67, following treatment for 72 hours with control or patient CSF and imaged with confocal
microscopy. Scale bar = 50 µm
(F) Quantification of parvalbumin (PV) and GAD65/67 staining intensity. Patient antibody
treatment caused a significant decrease in somatic parvalbumin staining intensity, but no change
in somatic GAD65/67 intensity (parvalbumin, 89.58±2.23% of control, n=7; GAD65/67,
111.1±4.55% of control; n=2). Asterisk indicates significance; Mann-Whitney test, p<0.05.
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CHAPTER 5. CONCLUSIONS & FUTURE WORK

The studies discussed in previous chapters have advanced our understanding of a novel
class of autoimmune encephalitides. My work using in vitro cell culture and slice models of antiNMDAR and anti-AMPAR encephalitis uncovered previously unknown pathogenic mechanisms
and homeostatic effects of patient antibody exposure. Data showed that patient antibody binding
to NMDAR or AMPAR caused a decrease in synaptic transmission through that receptor via
internalization (Fig 1, schematic for anti-NMDAR encephalitis). This glutamatergic hypofunction
led to compensatory changes in inhibitory synapse strength and intrinsic excitability, which
altered spontaneous action potential firing in response to remaining synaptic input.
To facilitate an in vivo examination of the circuit dysfunction and behavioral impairments
of these disorders, an animal model of anti-NMDAR encephalitis has recently been developed
1

and validated. Mice are infused intraventricularly with patient antibodies for 14 days, and
continue to be monitored up through 46 days. Antibody deposition and NMDAR down-regulation
peak at 18 days, then subsequently recover. Patient antibody-infused mice have memory
impairments, anhedonia, and depression, without changes in anxiety, aggression, or locomotor
activity. Thus, the animal model exhibits many features, both histological and behavioral, of
human patients.
This exciting in vivo work opens the door for a myriad of studies. Homeostatic changes in
response to patient antibody treatment can be monitored in vivo, in distinct circuits and cell types
(interneurons, pyramidal neurons). Further dissection of the mechanisms of plasticity can be
undertaken, as well. For example, what specific ion channels underlie the increased excitability in
response to anti-NMDAR and anti-AMPAR antibodies? What conductances facilitate the
transition to a more ‘bursting’ phenotype in response to anti-AMPAR antibody treatment, and
does a similar change occur after anti-NMDAR antibody treatment?
Several conductances are known to contribute to burst firing, including those underlying
after-hyperpolarizations (IKCa2+, a calcium-dependent potassium current) and depolarizing after131	
  

potentials (INaP, persistent sodium current; IT, low-threshold activated calcium current).

2-5

Additionally, synaptic mechanisms can regulate burst firing. Inhibition by GABAARs and
GABABRs decreases, and blockade of GABAARs by bicuculline enhances, the tendency to fire in
bursts.

6-8

Apart from mechanisms, the functional and behavioral implications of this change in

action potential firing are best addressed in an animal model. Burst firing has been proposed to
improve the signal-to-noise ratio and to increase the reliability of presynaptic vesicle release.

9

This may result in inappropriate gating and over-responsiveness to stimuli, as well as triggering
seizures.
NMDARs and AMPARs are involved in Hebbian as well as homeostatic plasticity.

10

Defects in spike-timing dependent plasticity and long-term potentiation and depression in
response to antibody infusion could be assayed in slices taken from treated animals with memory
impairments. It would be interesting to know if, in addition to the anti-glutamate receptor
encephalitides, other autoimmune diseases of synapses, such as those targeting GABABRs,
GABAARs, LGI, and CASPR2, induce homeostatic plasticity. Finally, the ‘sensor’ that the neurons
use to monitor their activity is unknown. In many systems intracellular calcium is thought to be the
read-out,

11-13

which could explain how and why NMDAR and AMPAR hypofunction trigger these

modifications.
The parallels between schizophrenia and anti-NMDAR encephalitis are fascinating and
largely unexplored. Both diseases share symptoms of psychosis and cognitive deficits, and
NMDAR hypofunction is likely to contribute to schizophrenia. Several genes linked to
schizophrenia impact NMDAR function, including NRG1, ErbB4, GluN2B, and DAAO.

14-16

We

showed a loss of parvalbumin immunoreactivity in response to anti-NMDAR antibody treatment
(Chapter 4, Figure 2), and this class of interneurons is implicated in the pathophysiology of
schizophrenia.

17-19

Recording from these neurons to see if physiological abnormalities also occur

in response to the direct loss of NMDAR transmission or the induction of homeostatic plasticity, or
both, could more strongly link the etiologies of these disorders. Performing EEGs on infused
animals to measure the power of gamma-frequency firing, which is dependent on PV+
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interneuron integrity and commonly disrupted in schizophrenia patients and animal models, is
another future experiment.
One of the most compelling questions, and certainly one of utmost clinical importance, is
the divergent time-course between clearance of anti-neuronal antibodies and amelioration of
symptoms. Long after antibodies are undetectable in serum or CSF, patients remain functionally
compromised. It can take up to two years for a full return to work and normal routine, and
sometimes even years after treatment people are left with cognitive deficiencies. A faithful
predictor of a good outcome is early intervention.

20

However, the persistent neurological problems

even in the absence of antibody exposure remain mysterious. In culture, receptor levels return to
baseline within a few days of antibody removal;

21,22

similarly, in an animal model, immunoglobulin

(IgG) clearance and recovery of NMDARs is complete within twelve days of cessation of antibody
infusion.

1

The various neurotransmitter systems of the central nervous system do not operate in
isolation, but dynamically modulate each other. The glutamate and dopamine systems, for
example, are intimately intertwined, and both are major players in psychosis and cognition. Longterm blockade of NMDARs leads to a decrease of mesocortical dopamine release, but an
increase of subcortical and mesolimbic dopamine.

23

This complex interaction is mediated by

glutamatergic projections from the prefrontal cortex and hippocampus. Conversely, dopaminergic
input modulates glutamate neurotransmission. D2 receptors inhibit glutamatergic transmission
within the striatum, while D1 receptors enhance it. The prefrontal cortex receives dopaminergic
projections from the ventral tegmental area (VTA), which tend to promote local GABAergic
inhibition of pyramidal neurons. Thus, a hypoglutamatergic state could lead to decreased
dopamine release from the VTA, and thus disinhibition within the cortex.

24-26

The exposure to autoantibodies in patients may therefore lead to a cascade of changes,
both within and between neurotransmitter systems. As antibody titers fall, even though receptor
density returns to normal, the brain may require additional time to reset to its pre-disease
baseline.
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Finally, an animal model of this disease lends itself to exploration of the field of
neuroimmunology and the brain-immune system interaction. Long thought of as an ‘immune
privileged’ space, the nervous system is now known to be subject to thorough surveillance by the
immune system. The characterization of the blood-brain-barrier has shifted from an impenetrable
gate to a dynamic interface with the immune environment.

27-29

In 2008, the majority of anti-

NMDAR encephalitis patients suffered from a paraneoplastic condition provoked by a
teratoma.

30,31

In 2014, less than half of the cases are associated with tumors, but the

immunological trigger has yet to be elucidated.

20

Additionally, for all patient samples examined,

the epitope is confined to a specific region of the GluN1 subunit of the NMDAR.

32

The reason why

this region is particularly antigenic is unknown.
Animal models of anti-glutamate receptor encephalitides can be powerful tools for
understanding the cellular, synaptic and circuit underpinnings of human behavior. In addition to
these models being clinically important for encephalitis patients, as well as patients with other
forms of psychosis and cognitive deficits, including schizophrenia, the potential for basic
neuroscience inquiry is enormous, and just beginning to be explored.
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Figure 1: Model of patient antibody induced dysfunction and homeostatic plasticity
(A) In the absence of patient antibodies, glutamate binding to NMDARs and AMPARs leads to an
influx of ions, including calcium, to depolarize the postsynaptic membrane and activate
intracellular signaling cascades.
(B) The postsynaptic neuron also receives inhibitory input from GABAergic synapses. The
presynaptic inhibitory terminal has vesicles containing the inhibitory neurotransmitter GABA,
which is released upon terminal depolarization and bind to postsynaptic GABAARs. This allows
for an influx of chloride ions, which hyperpolarizes the postsynaptic membrane. The combined
action of these opposing inputs, excitatory and inhibitory, leads to some pattern of action potential
firing in the postsynaptic neuron, which is also influenced by voltage-gated ion channels within
the neuronal membrane.
(C) After patient antibodies bind to NMDARs, they are internalized and lost from the synapse.
This causes a decrease in both intracellular calcium and postsynaptic depolarization. In
response, inhibitory synapses are homeostatically downregulated through a reduction in the
presynaptic vesicular GABA transporter, vGAT, which loads GABA into presynaptic terminals.
This leads to a reduction in inhibitory currents. At the same time, the intrinsic excitability of the
postsynaptic neuronal membrane increases, further compensating for the loss of excitatory
neurotransmission. This is likely mediated through changes in one or more voltage-gated ion
channels that together shape excitability and firing properties of the membrane. These changes in
inhibitory synapses and intrinsic excitability are not able to normalize action potential firing and
lead to a more bursting pattern, which may contribute to seizures and neuropsychiatric symptoms
in patients. There are several outstanding questions that remain, the loci of which are labeled by
question marks. First, what is the postsynaptic signal that triggers the cascade of changes
leading to homeostatic plasticity? In many systems, this has been found to be calcium influx,
through NMDARs, voltage-gated channels, or intracellular stores. Second, how does this signal
lead to non-cell autonomous changes in inhibitory synapses? This could be a diffusible
messenger, such as nitric oxide or endocannabinoids, or could be a retrograde signal through a
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neurotrophin such as BDNF. Third, once this signal has been transmitted across the synapse,
does it cause a decrease of vGAT at a transcriptional or translation level? Finally, how is intrinsic
excitability modified? A variety of voltage-gated conductances are well positioned to enhance
action potential firing and convert a more tonic firing into bursting. Answers to these questions
should further clarify the induction and expression of the multitude of homeostatic changes that
occur upon loss of glutamate transmission in these autoimmune encephalitides.
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